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CHAPTER 1 
 
Introduction: 
 
Folate, a water-soluble B vitamin, has emerged as an important nutritional 
element in the pathogenesis of several malignancies, including cancers of the 
colorectum, lung, pancreas, esophagus, stomach, cervix, and breast, as well as 
neuroblastoma and leukemia. Studies have collectively implied an inverse 
association between dietary and serum folate and the risk of malignancy (1, 2). 
The most convincing relates to colorectal cancer (3, 4). 
 
Folate Digestion, Absorption and Metabolism 
 
Folate is the naturally occurring form of the vitamin found in foods, which 
have similar nutritional properties of folic acid (5, 6). The U.S. RDA for folate is 
400 micrograms per day for nonpregnant ages 19 to 50 years. Folic acid (aka 
pteroylmonoglutamic acid), is rarely found in natural food items but is the source 
used in the fortification of foods and supplements (7). Dietary folate is only about 
50% bioavailable (8), whereas folic acid is 85% bioavailable (9). Bioavailablity is 
dependent on the length of the polyglutamate chain to which most of the natural 
folate is attached. Digestion of folates begins in the small intestine. Initially, 
folylpoly-glutamate carboxypeptidase, a brush border enzyme, removes dietary 
folate polyglutamates up to their corresponding monoglutamate derivatives, 5-
methyltetrahydrofolic acid and 5-formyltetrahydrofolic acid, through removal of 
glutamate residues. These monoglutamates, which now carry a reduced negative 
charge, are subsequently actively absorbed, mainly in the jejunum, via the 
reduced folate carrier (RFC) or the protein-coupled folate transporter and 
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converted  to  tetrahydrofolic  acid  (THF)  by  dihyrofolate  reductase  (DHFR),  an 
 
NADPH-requiring enzyme. THF is subsequently converted to 5-methyl-THF and 
then transferred to the portal circulation which are taken up by the liver or 
converted to 5-methyl-THF, before entering the plasma. From the plasma, 
specific  carriers  (RFC)  or  receptors  (folate  receptors  α or  β)  transport  5-methyl- 
 
THF into cells. 5-methyl-THF undergoes polyglutamation altering the properties 
of the molecule such that transportion through the membrane is inhibited and 
causing an accumulation in the liver and cells. Enzymes involved in folate 
metabolism have a higher affinity for polyglutamate forms of folate. Many of the 
inter-conversions of folates are oxidation-reduction reactions that utilize NADH, 
 
NADPH and ATP. It should be noted that folates may also be absorbed through 
the colon due to microbial folate production. Here the absorption rate is 
estimated to be ~50 times lower than in the small intestine; however, it may 
contribute significantly to total folate absorption (10). 
 
Folate in one carbon metabolism 
 
Folate  has  an  essential  role  as  a  one  carbon  donor  in  DNA  metabolism 
 
(Fig. 1) (11). It functions as a methyl donor through 5-methyltetrahydrofolate, 
remethylating homocysteine to methionine, which in turn is converted to S-
adenosylmethionine (SAM), the primary intracellular methyl donor. 
Subsequently, SAM methylates specific cytosines in DNA and this regulates 
gene transcription. In addition, folate through 5,10 methylene THF, donates a 
methyl group to uracil (U) converting it to thymine, crucial for DNA synthesis and 
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repair (12). 5,10 methylene THF can be oxidized to form 10-formyl-THF for 
denovo synthesis of purines (13, 14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 
 
Folate and disease 
 
Since the installation of folate fortification of cereal grains by the Food and 
 
Drug Administration, to eradicate NTDs, median RBC folate levels of women of 
childbearing age increased 65%, from 160 ng/mL to 264 ng/mL between 1988 
to1994 and 1999 to 2000. The NHANES 2005 to 2006 value is 257 ng/mL. In 
addition, the prevalence of low RBC folate among U.S. women of childbearing 
age declined from 37.6% in 1988 to 1994 to 5.1% in 1999 to 2000. The 2005 to 
 
2006  value  was  4.5%  (15).   Honein  et  al.  (2001)(16),  report  a  19%  reduction  in 
 
NTD birth prevalence following folic acid fortification of the US food supply. 
Despite this massive effort, however, there remains a high incidence of diseases 
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like CVD, stroke, Alzheimer’s disease, depression and cancer. It is suggested 
that these disease states continue to prevail potentially as a result of genetic 
disorders of enzymes involved in folate metabolism, increasing age, and alcohol 
useage. 
Aberrations in folate metabolism include polymorphisms in a number of 
essential genes related to this pathway. One example is that of the RFC, as 
previously described, whose variations can give rise to a variety of cancers (17, 
18 and 19). As well, mutations in the Folate receptor-alpha (FR-alpha) gene 
which binds and transports folates, namely 5-methylTHF, into cells have been 
documented. Polymorphisms in this gene are said to contribute to 
hyperhomocysteinemia (20) increasing the risk of disease. 
Methylenetetrahydrofolate reductase (MTHFR) is an enzyme responsible for the 
conversion of 5,10-methyleneTHF to 5-methylTHF, a cosubstrate for the 
remethylation of homocysteine to methionine. Two well studied polymorphisms 
of this gene include MTHFR C677T, which is a C→T variation at nucleotide 677 
 
(C677T), as a results of alanine to valine substitution in the MTHFR protein and 
 
MTHFR    A1298C    (A→C;    glutamic    acid    substitution    to    alanine). Both 
 
polymorphisms lead to reduced MTHFR activity, resulting in the accumulation of 
 
5,10-methylene   THF   and   a   decrease   of   5-methyl   THF   (21)   contributing   to 
 
hyperhomocysteinemia. Other       genetic       variations       include       serine 
 
hydroxymethyltransferase (SHMT) (C→T substitution), which catalyzes the 
reversible conversion of serine and THF to glycine and methylene THF, thus 
providing one carbon units for synthesis of methionine, thymidylate and purine in 
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the cytoplasm, and methionine synthase (MS, A→G substitution) which catalyzes 
the transfer of methyl base from 5-methyl THF to homocysteine, producing 
methionine and tetrahydrofolate. The aforementioned is critical for maintenanace 
of SAM levels for DNA methylation and safeguarding of homocysteine levels. 
SHMT polymorphisms have been observed in ovarian (22), lung (23) and 
squamous cell carcinoma of the head and neck (24). Additionally polymorphisms 
are seen in variable number tandem repeats (VNTRs) for thymidylate synthase 
which catalyzes the conversion of dUMP to dTMP and thus plays a critical role in 
maintaining a balanced supply of deoxynucleotides required for DNA synthesis. 
 
Aging has profound effects on 1-carbon metabolism, discernible by 
hyperhomocysteinemia, genomic DNA hypomethylation, and impact on DNA 
repair systems. Achlorhydria, which is a lack of hydrochloric acid in digestive 
juices, is a common physiological change that occurs with aging (25). A pH < 7 is 
required for optimal absorption of folate monoglutamate (26), as such, 
achlorhydria can result in reduced folic acid absorption and folate depletion (25, 
27). Ethanol associated folate deficiency can develop because of poor dietary 
practices, intestinal malabsorption, altered hepatobiliary metabolism, enhanced 
colonic metabolism, and increased renal excretion of folate secondary to alcohol 
consumption. Ethanol reduces the intestinal and renal uptake of folate by 
changing the binding and transport kinetics of folate transport systems. Also, 
ethanol may lead to a folate deficiency as a result of reduced expression of folate 
transporters in both intestine and kidney contributing to folate malabsorption (28). 
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Folate Deficiency and Cancer 
 
Over the last several decades’ research studies have indicated an 
inverse association of low dietary folate intake and the development of certain 
cancers such as those of the esophagus, stomach, breast, leukemia, pancreas 
and others with the evidence most compelling for colon cancer. Larsson et 
al.(29), conducted a meta-analysis for studies published through March 2006 
which supported low dietary folate intake with increased risk of esophageal 
squamous cell carcinoma, esophageal adenocarcinoma and pancreas, cancers 
that were 40%–50% less likely to develop when dietary folate intake was high. 
 
Most,  although  not  all,  showed  an  increased  risk  of  these  cancers  with  the 
 
MTHFR 677TT genotype, which disrupts folate metabolism. Others have shown, 
in mucosal tissue samples from patients with gastric cancer, a lower folate 
concentration, detected by the FOL ACS:180 automated chemiluminescence 
system, then in controls (30). Likewise, Gao et al. (31) observed a significant 
inverse relationship in 669 breast cancer cases between folate intake and breast 
cancer risk. Of interest, Giovanucci et al. (32), in their study of 88 756 women 
from the Nurses' Health Study showed a reduced risk of development of colon 
cancer with long term high folate intake. In addition, animal studies have 
demonstrated time constraint for folate supplementation with initiation prior to the 
establishment of neoplastic foci essential for suppression of development and 
progression of cancer. If supplementation coincides with preexisting foci 
formation, this B-vitamin can enhance the growth of these preneoplastic lesions 
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(33, 34 and 35). Lindzon et al. (2009)(36) in their male Sprague-Dawley rats 
showed an increase in progression of colonic preneoplastic lesions to colon 
tumors when folic acid was supplemented six weeks post-ACF induction. 
It is believed that the mechanism of folates protection may be a result of 
the maintenance of normal DNA synthesis and DNA methylation (37). If folate is 
deficient, 5-methylTHF will not be sufficient to provide the methyl group to 
methylate homocysteine to methionine, SAM will become depleted. This would 
give rise to abnormal metabolism of methyl groups which impacts DNA 
methylation, a cellular process that may be detrimental in neoplastic 
transformation (38). Atypical methylation of cytosine residues of cytosine-guanine 
dinucleotide pairs impacts epigenetic gene expression and also has a role in 
maintaining DNA stability. Hypermethylation of promoter regions has the ability to 
silence tumor suppressor genes, which inhibit uncontrolled cell growth that could 
lead to the formation of tumors. In contrast, global hypomethylation of 
protoncogenes may cause their overexpression, a root for the transformation of 
normal cells into cancer cells via chromosomal instability and increase mutational 
frequency (39). As well, if cellular folate becomes deficient DNA stability may be 
reduced by a disruption in the nucleotide pool, negatively altering DNA synthesis 
and repair. Reduced synthesis of thymidylate from the imbalances in the 
deoxyribonucleotide pool results in massive uracil misincorporation into the DNA, 
leading to “a catastrophic repair cycle”. This may lead to DNA strand breaks, 
deletions, chromosomal breaks, micronucleus formation and loss of 
heterozygosity (40, 41, 41). In contrast, folate supplementation after 
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development of preneoplastic lesions maybe attributed to folate's tumor 
promoting effect (43). Cancer cells are cells that are categorized as having rapid 
levels of DNA replication and cell division occurring. Folate once again is the 
cofactor in the synthesis of nucleic acids and is required for DNA repair, which 
would only facilitate the growth of preneoplastic cells. If one considers the basis 
of use of antifolates in the treatment of certain cancers, it would only seem 
practical to recognize that a reduction of folate would cause inhibition of tumor 
growth. 
 
The Base Excision Repair Pathway (BER) 
 
BER is the predominant pathway in mammalian cells for repair of small DNA 
base lesions and abasic sites which arise spontaneously as a result of alkylation, 
oxidation and deamination events (44, 45, 46). It is estimated that BER is 
responsible for the repair of as many as one million nucleotides per cell per day 
 (47). In general, the BER pathway involves the following steps: i) DNA 
glycosylase enzymes remove damaged nucleic acid bases (purines or 
pyrimidines), ii) Endonuclease enzyme cleaves the phosphodiester backbone, iii) 
synthesis of new DNA by a DNA polymerase using the complementary strand as 
a template, iv) excision of the 5’-deoxyribose phosphate (dRp) terminus, v) 
recreation of the phosphodiester bond by a ligase (48). Two subpathways of BER 
have been recognized: ‘short patch’ which is responsible for the replacement of a 
damaged base with a single new nucleotide, and the ‘long patch’ which results in 
the replacement of approximately 2-10 nucleotides 
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including the damaged base (49). The ‘short patch repair pathway is the 
dominant pathway representing approximately 75-90% of all BER (50). 
‘Short-patch’  base  excision  repair:    The  short-patch  repair  pathway  is  a 
 
DNA polymerase ß-dependent pathway (51). There are two types of 
glycosylases, monofunctional and bifunctional. In monofunctional glycosylase-
initiated BER, a damaged or improper base is recognized and removed by 
enzymatic hydrolysis of the N-glycosyl bond creating an AP site. This AP site 
serves as a substrate for the endonuclease APE, which nicks the backbone 
directly 5’ of the AP site, creating a single strand break with a normal 3’-hydroxyl 
 
group and an abnormal 5’dRP terminus. β -pol then inserts a new base followed 
by the excision of the of the abnormal 5’dRP (52). This latter step has proven to 
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be rate limiting (53). In bifunctional glycosylase initiated BER, a DNA specific 
glycosylase recognizes the damaged base, excises it and makes an incision in 
the backbone with its associated AP lyase activity, yielding a normal 5'-terminal 
deoxynucleoside-5'-phosphate residue and an abnormal 3'-terminal α,β-
unsaturated aldehyde residue that must be processed prior to completion (53). 
By virtue of its 3’phosphodiesterase activity, Ape 1 performs this rate-limiting step 
that excises the deoxyribose fragments and phosphate groups at the 3’ terminus 
of DNA (54). Completion of BER requires seal of the nicked phosphodiester 
bond, the majority of which is completed by a complex of XRCC1 and DNA ligase 
III (55). 
 
‘Long-patch’ base excision repair: If damage is refractory to dRP moiety 
excision, then ‘long patch’ BER completes the repair. In this pathway, DNA 
 
polymerase β or e adds a few more nucleotides to the 3’-end of the nicked AP 
site (56) creating a flap that is removed by a flap endonuclease (FEN1) (57). The 
 
DNA ends are subsequently sealed by DNA ligase I (58).  It has been shown that 
 
cells  insufficient  in  β -pol  were  deficient  in  ‘short-patch’  BER,  but  proficient  in 
 
‘long-patch’ BER.  This suggests thatβ -pol is the polymerase in the ‘short-patch’ 
 
BER, whereas DNA polymerase β or ε are the main polymerases of the ‘long-
patch’ BER pathway (59). 
 
The BER deficient mouse model 
 
Based on β-pol role in the BER pathway on removal of uracil, alkylated 
and oxidized bases we decided to utilize the β-pol haploinsufficient mouse model 
to study the effects of folate deficiency in colon carcinogenesis. While 
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homozygous deletion of the β-pol gene in the mouse germ line results in lethality, 
 
β-pol+/-   heterozygote  transgenic  mice  appears  normal  and  fertile.     We  have 
 
previously characterized the β-pol+/- mice as having a 40 to 50% reduction in 
mRNA β-pol levels and a 50 to 60% decrease in β-pol protein levels. 
Additionally, we have shown an increased accumulation of SSBs and 
chromosomal aberrations that occur spontaneously in this animal model relative 
to their WT littermates. These incidences are exacerbated with the inclusion of 
oxidizing and alkylating agents and in addition demonstrate an increase in 
mutational frequency (60). These happenings proved similar to the DNA damage 
that is induced in folate deficiency making it plausible to further study the 
connection between this repair pathway and folate. 
 
Polymerase β is indispensible in ‘short patch’ repair for both its lyase and 
gap filling. It appears that β-pol also has a role in ‘long patch’ repair by the 
insertion of several nucleotides (61). Examples of base lesions repaired by BER 
pathway include oxidized bases such as 8-oxoguanine, 2,6-diamino-4-hydroxy-5-
formamidopyrimidine, alkylated bases like 3-methyladenine, 7-methylguanine, 
deaminated bases like hypoxanthine that arise from the deamination of adenine or 
uracil formed by deamination of 5-methylcytosine or its misincorporated in DNA. 
Although the ‘short patch’ repair pathway is the dominant pathway representing 
approximately 75-90% of all BER (50), β-pol has an important role in both BER 
pathways. Accordingly, removal of β-pol would be reasonable to study the BER 
deficient model. We have previously (62) shown that WT animals exposed to 
oxidative damage had increased BER and β-pol levels, whereas, β- 
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pol haploinsufficient mice, as previously mentioned, exhibited a greater 
occurrence of SSB than WT (60). 
ββ-pol+/-  Mice as a Model for BER Polymorphisms 
 
β-pol is a monomeric polypeptide of 335 amino acids consisting of two 
domains: an 8-kDa amino-terminal lyase domain and a 31-kDa active site 
carboxy-terminal polymerase domain (63, 64). The amino-terminal domain is 
involved in binding to single stranded DNA, recognition of the 5’-phosphate in 
gapped DNA, removal of the 5’-dRP group from AP endonuclease-incised DNA, 
and AP-site strand incision (65). The carboxy-terminal domain binds weakly to 
double stranded DNA and possess nucleotidyltransferase activity (63, 66). β-pol 
is located on the proximal region of the short arm of chromosome 8 (p12-p11) 
(67). 
 
The  Heydari  lab  has  previously  shown  that  β-pol+/-   results  in  genomic 
 
instability (68). The β-pol haploinsufficient mouse has a reduced ability to tolerate 
carcinogen exposure, demonstrating reduced BER capacity and this translates 
into concern regarding the development of certain cancers. In fact, 
mutations in the gene encoding β-pol have been previously identified in human 
colorectal, prostate, lung and breast carcinomas (69, 70, 71, 72). These 
mutations are found only in the tumor tissue and not in the adjacent normal 
tissue, thus corresponding to sporadic mutations (73). 
 
Studies have shown that approximately 30%of human tumors are 
characterized by mutations in β-pol including those of the colon, prostate, lung, 
breast and bladder (Starcevic et al, 2004). In particular those of the colon include 
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a β-pol single nucleotide polymorphism (SNP) where positively charged Lys-289 
was substituted for a neutral Met (K289M). This variant leads to altered 
positioning of DNA within the K289M enzyme leading to misincorporation of 
nucleotides (74) during BER, lowering its fidelity. In Lang’s study they utilized cII 
mutants from cells expressing K289M showing an increased frequency of C to G 
base substitutions within the AACAAA sequence. This polymorphism observed 
resembles the mutational hotspot within the APC gene, a gene that is frequently 
mutated in colon carcinoma. Wang et al. (75), observed this alteration in human 
colorectal carcinomas, a mutation found only in the tumor tissue and not in 
normal, surrounding mucosa (74). These abovementioned findings indicate that 
this variant could impact the cell through haploinsufficiency and modify risk for 
colon cancer. This SNP, along with others found in various tissues (I260M 
prostate carcinoma and E295K gastric carcinoma, (76)), confer that the β-pol 
haploinsufficient animal can serve as a model mimicking human polymorphisms. 
 
We have previously shown that β-pol haploinsufficiency results in genomic 
instability (60). Furthermore, β-pol haploinsufficient mice display an acceleration 
of normal, age-related tumors, e.g., lymphomas, as well as increased 
susceptibility to epithelial tumors, such as adenocarcinomas, phenomenon that 
do not typically occur to a high degree in C57BL/6 mice (77). Consequently, 
previous experimental work done in our lab and others strengthens the cause for 
 
using a β- pol haploinsufficient mouse as a model to study CRC. 
 
 
 
 
Folate deficiency and Base Excision Repair 
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While uracil is not a normal constituent of DNA it can arise in DNA during 
replication when dUMP:dTMP ratios are imbalanced. It may also arise as a result 
of the deamination of cytosine which is the hydrolysis reaction of cytosine into 
uracil. The frequency of cytosine deamination is elevated when SAM levels are 
reduced (78), as seen in folate deficiency. The DNA repair pathway primarily 
responsible for removal of uracil is the base excision repair (BER) pathway. 
Misincorporation of uracil, as seen in folate deficiency (79), constitutes a 
nucleotide that is normally repaired by the ‘short-patch’ BER pathway. Briefly, the 
removal of uracil by BER involves i) uracil-DNA glycosylase (UDG) binding 
specifically to the affected base and hydrolyzing the N-glycosidic bond, releasing 
the damaged base while keeping the DNA backbone intact. ii) The abasic site is 
subsequently recognized by an endonuclease, notably Ape 1, which nicks the 
phosphodiester backbone immediately 5’ to the lesion leaving a strand break with 
a normal 3’-hydroxyl group and an abnormal 5’dRp residue. iii) synthesis of new 
DNA by incorporation of the correct nucleotide by DNA polymerase, iv) excision 
of the 5’dRp moiety, and v) ligation by a DNA ligase (Ligase 1 or Ligase 
 
3/XCRR1 (1). 
 
Evidence from our lab, as well as others, demonstrate a reduced ability to 
process DNA damage when folate deficiency is present. We have shown that 
folate deficient mice display an initiation of BER, as observed by an increase in 
uracil DNA glycosylase; however there is a stalling at the rate-limiting enzyme 
DNA polymerase β. Consequently, we observed an accumulation of DNA single 
strand breaks (80), which if left unrepaired could emerge as a DNA double strand 
15 
 
 
break. Similarly, Blount et al.(81) using folate deficient human erythrocytes, 
showed increased levels of uracil in DNA as well as, an increase in micronuclei 
formation. In addition, Branda et al. (82) have demonstrated that folate deficient 
Weanling Fischer 344 rats are less able to repair damages induced by alkylating 
agents. Although they show that folate deficiency on its own was mutagenic, in 
conjunction with ENU, an alkylating agent, it was found to be even more 
mutagenic. Branda has also shown (83) that folate deficiency acts synergistically 
with EMS in CHO cells to increase DNA strand breaks and mutant frequency. 
Duthie and Hawdon (84) have shown that folate depletion in human lymphocytes 
makes the cells more sensitive to oxidative damage induced by hydrogen 
peroxide. Duthie et al. (85) have further shown that human colon epithelial cells 
grown in the absence of folate are poorly able to repair damages induced by 
 
MMS (an alkylating agent) and hydrogen peroxide (an oxidizing agent). Growth in 
a low folate medium has also been shown to impair excision repair capacity of 
colonocytes (86). More oxidative damage, which is repaired by BER, 
accumulates in response to amyloid β-peptide in neuronal cells depleted of folate 
 
(87). These data indicate that the pathway responsible for repairing these 
damages may be ineffective when folate is limiting. These findings are rather 
compelling for the effects of folate on cellular DNA appear to mimic those that are 
seen when β-pol is deficient. We would suggest that this phenomenon occurs 
conceivably by overwhelming the capacity of BER through inhibition of its rate 
determining enzyme, DNA polymerase β. Specifically, we have previously shown 
that with β-pol haploinsufficiency, there is a lack of induction of β-pol and 
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an  accumulation  of  SSB  (60),  much  the  same  as  perceived  in  folate  deficiency 
 
(80). 
 
Colon Cancer 
 
In the US, colorectal cancer is the second leading cause of cancer-related 
death and accounts for approximately 25% of all cancer deaths in the Western 
world. It is believed that 85% of CRC cases are caused by sporadic mutation, 
that is, it occurs in people who have no (or very little) family history of the disease 
and therefore is due to diverse environmental risk factors. The remaining CRC 
cases are thought to be a result of genetic predisposition notably hereditary 
nonpolyposis colorectal cancer (HNPCC) and familial adenomatosis polyposis 
 (FAP) (88). Sporadic Colon Cancer occurs in people who have no (or very little) 
family history of the disease and generally occurs in individuals over age 50 
years. It has been stated that inactivation of the APC gene is found in about 85% 
and inactivation of the mismatch repair genes, including MSH2, MLH1, and 
PMS2, is found in the remaining 15%of sporadic colon cancers (89). Hereditary 
nonpolyposis colorectal cancer (HNPCC) is the more common form of hereditary 
colon cancer. It is an autosomal dominantly inherited condition characterized by 
an early onset of either colon, endometrial, ovarian, urinary tract, stomach, small 
bowel, biliary tract, or brain cancers. The average age of diagnosis is 44 years 
for colon cancer. It is estimated that 5 genes related to mismatch DNA repair are 
responsible for the development of this disease (90). This condition gives rise to 
a modest number of polyps in the colon beginning in the third or fourth decade of 
life (90) and are described as highly villous and dysplastic with a rapid 
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progression to cancer (90, 91). FAP is an inherited condition that results from 
defects in the adenomatous polyposis coli (APC) gene. APC is a known tumor 
suppressor that prevents the uncontrolled growth of cells that may result in 
cancerous tumors. If this gene develops a mutation, the protein made by APC 
cannot suppress cellular overgrowth leading to the formation of polyps, which 
can overtime become cancerous. Polyp formation begins in early adolescence 
with the number and size increasing with time. The pathology of polyps in FAP is 
indistinguishable from sporadic colon cancers; however, due to the vast number 
and early development of polyps, most individuals with FAP will develop colon 
cancer (90). 
 
Progression of colon cancer is thought to occur over a period of many 
years in a multistep process involving a series of pathological alterations ranging 
from discrete microscopic mucosal lesions, like aberrant crypt foci (ACF), to 
malignant tumors (92, 93). Subtle alterations in the regular pattern of ACF are 
among the first histologically detectable changes that may be linked with 
colorectal cancer development (CRC) (94, 95, 96). The growth, morphological 
and molecular features of ACF supports the line of reasoning that ACF are 
putative preneoplastic lesions (97). Bird (92) was the first to describe ACF in the 
colonic mucosa of rodents exposed to colorectal carcinogens. These ACF which 
have long been considered as preneoplastic lesions and precancerous lesions, 
appear larger, with a thicker epithelial lining than adjacent normal crypts and 
dilated irregular luminal openings rising above the surrounding mucosa. These 
lesions have been observed as early as two weeks after administration of the 
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colon carcinogen DMH (98). Evaluation of solitary crypts demonstrates the 
aberrant crypts divide by fission beginning near the base of the crypt (99) 
growing overtime to form a focus with multiple aberrant crypts (100). ACF in 
humans closely resembles the aberrant crypts detected in rodents treated with 
carcinogens (101). It should be noted that although the number of ACF increases 
with increased exposure to carcinogens little evidence supports tumor 
development with increasing numbers (102). In other words, aberrant crypts do 
not indicate that colon cancer is imminent. 
 
Base Excision Repair, Folate Deficiency and Colon Cancer 
 
The association between BER, dietary folate and colon carcinogenesis is 
probably linked to folate deficiencies role in the ‘catastrophic repair’ cycle that 
arises due to extensive DNA damage secondary to decreased synthesis of both 
thymidylate and purines. Under thymidylate duress, BER is inefficient in repair 
due to the resynthesis step where elevated dUTP causes reintroduction of 
genomic uracil. Uracil may arise in DNA, in small quantities as a result of 
spontaneous cytosine deamination or/and misincorporation of dUMP during DNA 
replication. Frederico et al. (103), using a genetic reversion assay conservatively 
estimated that this occurs approximately 50 times per cell per day in the human 
genome. With folate deficiency, however, the rate of cytosine deamination 
increases as much as 10,000-fold (78). This rate would likely stress or overwhelm 
the DNA repair pathway, leading to single strand breaks that if left unrepaired are 
clastogenic (104). This can give rise to sections of the 
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chromosome being deleted, added, or rearranged, hence the inception of 
mutagenesis which can further develop to carcinogenesis. 
 
Introduction of other DNA repair pathways 
 
NHEJ is considered to be responsible for resolving DSBs that occur in the 
 
G1 phase of the cell cycle, while HR is responsible for resolving DSBs during S 
and G2 phases. NHEJ is an error prone pathway, whereas HR is quite accurate 
(104). There have been reports of cross-talk between homologous recombination 
(HR) and BER. It is said that HR responds to persistent BER strand break 
intermediates (Wyatt et al., 2006) which would seem appropriate as SSB can 
give rise to DSB if left unrepaired. The demand for deoxynucleotides required for 
the resynthesis step of HR can extend up to thousands of nucleotides in 
comparison to the 1 to 5 nucleotides required to complete BER, presenting a 
problem with folate is deficient. Use of HR when nucleotide pools are imbalanced 
would appear to be deleterious, nevertheless it may be the only way to recover 
stalled and/or collapsed replication forks. Currently there is a lack of evidence for 
a role of NHEJ in folate deficiency, 
 
Folate Deficiency and mismatch repair 
 
Mismatch repair is a system for recognizing and repairing of damage 
incurred during DNA replication. Mutations in MMR genes results in microsatellite 
instability (MSI) which is instability of repeated sequences of DNA. Research has 
shown that MSI has a frequency of 10% to 20% in colon cancers which is 
attributed to both MLH1 promoter hypermethylation and germline mutations in 
MMR genes (MLH1, MSH2, MSH6, PMS1, and PMS2, (105, 106). 
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Poynter et al. (106) have also shown that 54% of population-based MSI cases 
had hMLH1 methylation. MSH2 and MSH6 detect DNA mismatches at which 
point they recruit MLH1 and PMS1to the repair sites. MLH1 proteins join with 
PMS2 to form the major complex for mismatch repair (107). This complex is 
responsible for the coordination subsequent repair events. Folate deficiency has 
also been observed to impair MMR, in nonneoplastic ulcerative colitis patients 
(108). It was believed that a defect in MMR in these patients might translate into 
an increased risk for mutations. Due to the fact that DNA methylation has a role 
in strand discrimination during postreplication MMR, aberrations in normal 
patterns of DNA methylation, which can occur with folate deficiency, might 
adversely affect this DNA repair mechanism. Both DNA hypomethylation which 
would impinge upon the methyl-directed MMR and methylation of CpG sites in 
the hMLH1 gene, which has been associated with MSI in colon and stomach 
cancer (109), can be induced by folate deficiency (110). Although BER and MMR 
have both been proven to have a basis in colon carcinogenesis, the causes 
 
are distinct defining the necessity to utilize β-pol-deficient animal model to 
directly test an effect of BER. 
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CHAPTER 2 
 
Hypothesis and Specific Aims 
 
Folate deficiency has been shown to result in low levels of nucleotide 
synthesis and in addition elevated levels of uracil being misincorporated in to 
DNA. Uracil incorporated into DNA is initially excised from DNA by uracil-DNA 
glycosylase at which time apyrimidinic endonuclease creates a nick in the DNA 
phosphate backbone. With massive uracil misincorporation as seen in folate 
deficiency it appears to create a ‘futile’ repair cycle in that there is an 
accumulation of transient single strand breaks that could result in a less 
repairable and more harmful double-strand breaks if two opposing nicks are 
formed. Accumulation of the aforementioned could result in chromosomal 
aberrations, increased mutational frequency and potentially the onset and 
progression of cancer, particular those of the colon. This scenario appears to be 
aped when β-pol is haploinsufficient. The objective of this research was, 
therefore, to elucidate the molecular mechanisms by which β-pol impacts colon 
cancer when folate is deficient. 
 
β-pol, being the rate limiting enzyme in the BER pathway, was expected to 
result in significantly deleterious effects when folate was deficient. It was thought 
that if β-pol were deficient, with the removal of uracil from the DNA by uracil-DNA 
glycosylase and the generation of transient SSBs that occurs with folate 
deficiency, this β-pol haploinsufficiency would create an extremely toxic level of 
unrepaired BER intermediates that would progress to ACF development and 
colon cancer progression. Thus, I tested the hypothesis that the accumulation of 
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DNA   damage,   preneoplastic   lesions   and   tumors   in   colon   caused   by   folate 
 
deficiency and carcinogen exposure will be accelerated by loss of β-pol. Using 
heterozygous β-pol in which one allele was inactivated and wildtype C57bl mice, 
I directly tested the impact of folate deficiency on BER activity in the β-pol 
haploinsufficient mouse model when exposed to the colon carcinogen DMH. 
 
Specific   Aim   1:     To   determine   whether   BER   deficiency   accelerates   the 
 
induction of ACFs induced by DMH when folate is deficient. That is, to test 
whether the accumulation of damages seen in folate deficiency results in the 
acceleration in onset and progression of precancerous lesions when β-pol is 
deficient. The accumulation of uracil, 
 
abasic sites and DNA single strand breaks can translate into toxic repair 
intermediates that create DNA damage in the form mutations when folate is 
deficient. I predicted that folate deficiency would increase the accumulation of 
 
DNA damage and mutational frequency in the β-pol+/- mice to a greater extent 
than it would in the wildtype mice due to the deficiency in base excision repair 
capacity. Both β-pol haploinsufficiency and folate deficiency on their own are 
genotoxic so it seemed only rational to assume that when combined the effects 
would be magnified with profound DNA damage and mutations and in contrast, 
the folate supplemented wildtype mice would prove resistant even after treatment 
with a colon carcinogen. This in turn would demonstrate that a folate deficit would 
further impair an already deficient BER pathway when β-pol is haploinsufficient. 
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Specific  Aim  2:  To  determine  whether  ββ-pol  haploinsufficiency  in  a  folate 
 
deficient  environment  accelerates  the  induction  of  tumors  caused  by  DMH 
 
when folate is deficient. As stated previously, ACF development does not imply 
that colon cancer is forthcoming. in fact, a majority regress, however, it is well-
established that an accumulation of DNA damage, mutations, or chromosomal 
abnormalities are initiating events in the genesis of cancer. Our 
 
previous studies have determined an increase in tumor development in β-pol mice. 
So this study aimed to determine if the combined effect of β-pol haploinsufficiency 
and folate deficiency would induce higher levels of ACF and if these putative 
markers were more likely to progress to neoplastic lesions. That 
 
is I depicted that folate deficiency imposed in a BER deficient environment would 
result in a more advanced ACF where they had increased proliferative capacity 
and reduction of cell death secondary to the mutational effects of lack of repair by 
β-pol haploinsufficiency. It seemed plausible to assume that the transformation in 
the DNA from this stressful environment would result in increased cell number 
 
(hyperplasia) progressing ACF to neoplastic lesions. 
 
Specific  Aim  3:    To  determine  the  impact  of  ββ-pol+/-   on  gene  expression 
 
when folate was deficient. Looking at gene expression analysis would help to 
elucidate the molecular mechanisms by which β-pol heterozygosity would 
influence ACF formation and colon tumorogenesis. Changes in expression of key 
genes could depict a more global indication of cellular mechanistic changes due 
to effects of β-pol heterozygosity in an environment deficient in folate. From this 
data we could not only elucidate changes in gene function but as well it may 
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highlight changes in key cellular pathways of colon carcinogenesis, such as cell 
 
cycle, apoptosis and colon carcinogenesis. 
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Abstract 
 
Aging    and    ββ-pol    deficiency   (ββ-pol+/− )    interact    to    accelerate    the 
 
development of malignant lymphomas and adenocarcinoma and increases 
tumor bearing load in mice. Folate deficiency (FD) has been shown to 
induce DNA damage repaired via base excision repair (BER) pathway. We 
anticipated that FD and BER deficiency will interact to accelerate aberrant 
 
crypt      foci      (ACF)      formation      and      tumor      development      in      ββ-pol 
 
haploinsufficient animals. FD resulted in a significant increase in ACF 
formation in wildtype (WT) animals exposed to 1, 2-dimethylhydrazine 
(DMH), a known colon and liver carcinogen; however FD reduced 
development of ACF in ββ-pol haploinsufficient mice. Prolonged feeding of 
 
the FD diet resulted in advanced ACF formation and liver tumors in wild 
type mice. However, FD attenuated onset and progression of ACF and 
prevented liver tumorigenesis in ββ-pol haploinsufficient mice, i.e., FD 
 
provided protection against tumorigenesis in a BER deficient environment 
in all tissues where DMH exerts its damage. Here we show a distinct 
downregulation in DNA repair pathways, e.g., BER, NER and MMR, and 
decline in cell proliferation, as well as an upregulation in PARP, 
proapoptotic genes and apoptosis in colon of FD ββ-pol haploinsufficient 
 
mice. Moreover, we report that FD BER deficient mice show a significant 
downregulation in mTOR pathway, which is implicated in cell proliferation 
and survival. Our data indicate, therefore, that FD in BER deficient mice 
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downregulates mTOR, inhibiting s-phase transit perhaps secondary to 
depletion of cellular energy by PARP, promoting apoptosis and providing 
protection against tumorigenesis. 
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INTRODUCTION 
 
Folate deficiency is an important public health concern because of the role 
folate plays in the development of many different health problems, including 
neural tube defects, cardiovascular disease, Alzheimer’s disease and cancer, 
specifically colon cancer. It has been proposed that the carcinogenic properties of 
folate deficiency may be related to a decrease in DNA methylation, perhaps as a 
function of reduced S-adenosylmethionine (SAM) levels, an increase in the uracil 
content of DNA or an increase in oxidative stress by alterations in thiol switches. 
Folate deficiency has also been shown to increase (in cells, animal models and 
humans) levels of single strand breaks (84, 111, 112, 85, 113), micronucleus 
formation, (114, 115), chromosomal aberration (116, 117) and mutation 
frequency (82, 83), all potentially downstream effects of high levels of uracil in 
DNA and oxidative damage to DNA. 
 
The DNA repair pathway for removal of uracil and oxidized bases is the 
base excision repair (BER) pathway. The BER pathway is believed to repair 
small, non-helix-distorting lesions in the DNA. It has been estimated to be 
responsible for the repair of as many as one million nucleotides per cell per day 
(47), stressing its importance in the maintenance of genomic stability. It has been 
suggested that BER has evolved in response to in vivo exposure of DNA to ROS 
and endogenous alkylation, and that this pathway suppresses spontaneous 
mutagenesis (117). In the initial elucidation of the BER pathway the following 
steps were involved: i) removal of the damaged base by a DNA glycosylase; ii) 
incision of the phosphate backbone by an endonuclease; iii) synthesis of new 
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DNA by a polymerase; iv) excision of the deoxyribose phosphate (dRp) moiety; 
and v) ligation. This remains the predominant BER pathway and is clearly the 
pathway for repair of uracil. DNA polymerase β (β-pol) performs the 
polymerization steps in the predominant short patch BER pathway and appears 
to perform the rate-limiting step, by virtue of its dRp lyase activity (53). In the 
process of uracil removal and repair of oxidized bases, a transient formation of a 
 
DNA single strand break occurs. Our laboratory has shown that 
haploinsufficiency in β-pol would result in persistence of the DNA single stand 
breaks, where this persistence could result in DNA double strand breaks and 
chromosomal aberration (60). 
 
Based on current understanding of the role of a β-pol-dependent BER 
pathway on removal of uracil, alkylated bases and oxidized bases, it is interesting 
to determine the impact of β-pol haploinsufficiency on tumorigenesis. While the 
homozygous β-pol knockout is embryonic lethal, the β-pol heterozygous knockout 
mice are viable and fertile. We previously characterized this mouse model as 
expressing 40-50% less β-pol mRNA and protein in various tissues and 
determined that this mouse has 40-50% reduced in vitro BER activity in all 
tissues tested (60). In addition, these animals exhibit an accumulation of 
spontaneously arising single strand breaks and chromosomal aberrations with 
age. Furthermore, in response to alkylating and oxidizing agents, an even greater 
accumulation of single strand breaks and chromosomal aberrations, as well as an 
increase in mutation frequency are observed in these mice (60). 
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Moreover, β-pol haploinsufficient mice display an acceleration of normal, age-
related tumors, e.g., lymphomas, developing alongside an increased 
susceptibility to epithelial tumors, e.g., adenocarcinomas, which do not typically 
occur at a high incidence in C57BL/6 mice (77). 
 
Based on the striking similarities between DNA damage induced by folate 
deficiency and that induced by a reduction in BER capacity, we suggest a strong 
association between BER and folate. We have reported previously that folate 
deficiency overwhelms the capacity of BER through the inhibition of upregulation 
of β-pol (80). It is feasible that the inability to induce β-pol when folate is deficient 
results in a functional BER deficiency, providing a logical explanation for the 
phenotype induced by folate deficiency. While a tight correlation between DNA 
damage and cancer exists, it is necessary to evaluate preneoplastic lesions and 
 
tumors  arising  in  response  to  the  interaction  between  β-pol  loss  and  folate 
 
deficiency. The purpose of this study is to determine whether β-pol 
haploinsufficiency accelerates the development and/or aggressiveness of these 
lesions in colon and liver in response to carcinogen, 1,2-dimethylhydrazine 
 
(DMH). This study has important human health implications, as polymorphisms 
within the human population may render individuals haploinsufficient for β-pol 
and increase cancer risk by reducing their DNA damage tolerance. 
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METHODS 
 
Animals-   Experiments   were   performed   in   young   4   to   6   month   old 
 
C57BL/6-specific  pathogen  free  male  mice  and  mice  heterozygous  for  the  DNA 
 
polymerase β gene (β-pol+/-) (77). All practices performed on animals were in 
agreement with the National Institutes of Health (NIH) guidelines for the care and 
use of laboratory animals. Mice were backcrossed to the C57BL/6 background. 
The Wayne State University Animal Investigation Committee approved the 
animal protocol. Mice were maintained on a 12-h light/dark cycle and given water 
ad libitum. 
 
Diets  and  Carcinogenic  Treatment-   After acclimation for 7 days, wildtype 
 
(WT) and β-pol+/- mice were randomly assigned to two dietary groups; a folate 
adequate (FA) or folate deficient (FD) AIN93G-purified isoenergetic diet (Dyets, 
 
Inc., Lehigh Valley, PA) as described previously (80). The FA group received a 
folate adequate diet containing 2 mg/kg folic acid. The FD group received a 
folate-deficient diet containing 0 mg/kg folic acid. Diets were stored at –20°C.  
1% succinyl sulfathiazole was added to all diets. One week after commencement 
of food ingestion, randomly selected mice from both FA and FD were injected i.p. 
with 1,2-Dimethylhydrazine HCL (DMH, 30 mg/kg body weight) in 10mmol/L of 
NaHCO3 (Fisher Scientific, Fair Lawn, NJ) once a week for 6 wks 
 (Figure2, panel A). Both food intake and body weights were checked twice 
weekly to monitor for signs of of toxicity, e.g., weight loss, and the diets were 
continued for 12 weeks. 
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Aberrant colonic crypt (ACF) analysis- Animals were anesthetized under 
CO2 asphyxiation, the abdominal cavity was opened and the colon excised, 
 
rinsed with cold PBS, cut longitudinally, and fixed flat overnight in 10% neutral 
buffered formalin. The colonic crypts were stained with 2g/L of methylene blue in 
PBS for 5 min. The number of ACF and aberrant crypts per foci were determined 
by light microscopy at 10X magnification in a blinded man ner. 
 
Realtime PCR- Total RNAs were isolated from the colon mucosa of mice 
using the RNeasy Mini Kit (Qiagen, Valencia, CA) per manufacturer's protocol. 
cDNAs were synthesized from 1 µg RNA using random hexamer primers 
(Promega, Madison, WI) and purified with the QIAquick PCR Purification kit 
(Qiagen). The levels of cDNAs were quantified using a LightCycler real-time 
PCR machine (Stratagene, La Jolla, CA). PCR reactions contained 3 µL purified 
cDNA, 12.5 µL qPCR master mix, and 0.5 µmol/L each of sense and antisense 
primers (Roche)(Table I). For all amplifications, PCR conditions consisted of an 
initial denaturing step of 95°C for 5 minutes followe d by 40 cycles of 95°C for 10 
seconds, and 60°C for 30 seconds, with a melting curve a nalysis from 60°C to  
95°C to confirm specificity. External standards were pre pared by amplification of 
cDNAs for each gene. The amplicons were cloned into pGEM-T Easy vector, 
linearized with appropriate restriction enzyme, and used to prepare external 
standard curves. The level of each transcript was normalized to GAPDH. Results 
are expressed as mean values from five animals per experimental group. 
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Western blot analysis- Western blot analysis was performed using 200µg 
nuclear protein as previously described (118). Upon completion of SDS–PAGE, 
the region containing the protein(s) of interest was excised and prepared for 
 
Western blot analysis, whereas the remaining portion of the gel was stained with 
GelCode blue stain reagent (Pierce Biotechnology) to ensure equal protein 
loading. Western analysis was accomplished using affinity purified polyclonal 
 
antisera developed against mouse β-pol. As an internal control for protein 
loading, membranes were reprobed with anti-Lamin B antibody (Santa Cruz 
Biotechnology, Santa Cruz, CA) The bands were visualized and quantified using 
a ChemiImager System (AlphaInnotech, San Leandro, CA) after incubation in 
SuperSignal West Pico Chemiluminescent Substrate (Pierce Biotechnology, 
Rockford, IL). Data are expressed as the integrated density value (I.D.V.) of the 
band per ∝g of protein loaded. 
 
Microarray assays- Total RNAs were isolated from the colon mucosa of 
mice using the RNeasy Mini Kit (Qiagen, Valencia, CA) per manufacturer's 
protocol. RNA samples were quantified with NanoDrop ND-1000 (NanoDrop 
 
Technologies, Inc, Wilmington, DE) and 260/280 ratio in the range of 2.0-2.2 was 
defined as acceptable. A quality check of the total RNA was performed using an 
Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). One micro liter of 
total RNA sample was applied on RNA 6000 NanoChip, and the assay was run 
on the Bioanalyzer to determine if the 18S and 28S ribosomal bands are defined 
and to ensure no RNA degradation was present. Optimal concentration used to 
check the RNA quality is 250ng/∝l. 
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Microarray    expression    profiling    was    conducted    by    Microarray    & 
 
Bioinformatics Facility Core at Wayne State University (Institute of Environmental 
 
Health Sciences, Detroit, MI) according to the manufacturer’s protocol. A 
balanced block experimental design was used: 4 microarrays were completed for 
each comparison, with each microarray representing 1 randomly selected labeled 
mucosal sample from each experimental group paired with 1 randomly selected 
FA WT labeled mucosal sample i.e. in total 4 mucosal RNA samples from FDWT 
cohybridized with 4 FAWT, 4 FDWT DMH treated cohybridized with 4 FAWT and 
 
4 FD β-pol+/- DMH cohybridized with 4 FAWT treated, representing 4 micorarrays for 
each experimental comparison. Samples on a given array were oppositely labeled 
with Alexa 647 and Alexa 555 dyes. The four microarrays for a given 
 
group (i.e., WT untreated, WT DMH or β-pol+/- DMH treated) represent samples 
from eight separate mice, providing consideration of biological variation. In total, 
 
12 arrays representing 24 mice (8 WT, 8 WT DMH-treated, 8 β-pol+/- DMH-
treated) were completed. Dye swaps were used to account for dye bias effects 
such that of the four arrays in a given phenotype group, two had FD treated 
samples labeled with Alexa 647 co-hybridized with control samples labeled with 
 
Alexa 555 while the other two arrays within the same phenotype group had 
opposite dye orientations. Microarrays were scanned using the Agilent dual laser 
DNA micorarray scanner model G2565AA, with 10 micron resolution. 
 
Microarray gene profile analysis- Microarray image analysis was 
performed with Agilent Feature Extraction software, version A.5.1.1. Hierarchal 
Clustering analysis was performed using GeneSpringGX V10 (Agilent 
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Technologies) software, and the parameters were set for centroid linkage which 
calculates the euclidean distance between the respective centroids of two 
clusters. False discovery rate for FDWT was 5.1%, 1.7% for FDWT DMH treated 
 
and 0.39% for FD β-pol+/- DMH-treated experimental groups. Heatmaps were 
created by inputting accession numbers of differentially expressed genes, at 
 
p<0.001, for FDWT and FD β-pol+/- DMH-treated experimental groups through 
DAVID functional annotation. Outputs revealed gene onotologies of differentially 
expressed genes, which were than compared to created differentially expressed 
gene lists of DAVID biological processes, such as apoptosis and DNA repair. 
 
Data sets were then combined for FDWT and FD β-pol+/- DMH-treated to 1 large 
data set in order to create heatmaps for each biological function. Gene ontology 
analysis was performed using Gene Ontology Tree Machine (GOTM), 
 
(Bioinformatics,Vanderbilt University), applying differentially expressed genes as 
depicted in the heatmaps`. We chose a single gene set analysis, where GOTM 
compares the distribution of single gene set in each GO category to those in an 
existing reference gene list from the mouse genome, identifying GO categories 
with statistically significant enriched gene numbers as determined by the 
hypergeometric test (p<0.01) (119, 120). Real time quantitative RT-PCR was 
used to confirm the data obtained for selected genes in DNA repair pathways as 
described above. 
 
Terminal deoxynucleotidyl transferase-mediated nick-end labeling of 
apoptotic cells in situ- Colon tissues were dissected, opened longitudinally, fixed 
 
in  10%  neutral  buffered  formalin,  embedded  in  paraffin  wax  then  cut  into  5 µm- 
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thick sections. Sections were put on slides for the in situ terminal 
deoxynucleotidyl tranferase-mediated nick-end labeling (TUNEL) (CHEMICON 
International Inc., Temecula, CA) as per manufacturer’s protocol. Cells with 
positive staining (brown staining) were considered as apoptotic cells and the 
number of apoptotic cells was determined as the percentage per crypt. 
 
5-Bromo-2-deoxyuridine (BrdU)-staining of proliferating cells in situ- Two 
hours prior to CO2 asphxyation, mice were injected i.p. with a BrdU solution (10 
 
mol/L, 1 mL per 100 g body weight) (5-Bromo-2’-deoxy-uridine Labeling and 
Detection Kit ll, Roche Diagnostic, Mannheim, Germany) to immunostain 
proliferating cells, following manufacturers instructions for paraffin-embedded 
tissues. Briefly, after CO2 asphyxiation, as mentioned above, colons were 
 
excised, and fixed in formalin. The tissue was then embedded in paraffin and 
sections of 3 – 5 ∝m were cut longitudinally the full length of the colon. Tissues 
were incubated in 10 ∝mol anti-BrdU monoclonal antibody for 1 hr at 37°C 
followed by incubation with anti-mouse-Ig-alkaline phosphatase. The labeling 
index was used to quantify cell proliferation, defined as the percentage of BrdU-
positive cells per crypt. 
 
Tumor Analysis- All animals were sacrificed at 40 weeks after the last 
dose of DMH, by asphyxiation with carbon dioxide, and all organs and tissues 
were examined for grossly visible lesions. Liver and colon tissues, including 
gross abnormalities, were fixed in 10% neutral buffered formalin, trimmed, 
embedded in paraffin, sectioned to a thickness of 5 to 6 µm, stained with H&E, 
and examined microscopically. Preparation of slides for histopathology 
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evaluation   was   performed   by   pathologists   at   the   Department   of   Pathology, 
 
Wayne State University. 
 
Statistical analysis- Statistical significance between means was 
determined using ANOVA, followed by the Fisher’s least significant difference 
test where appropriate (121). P-values less than 0.05 were considered 
statistically significant. 
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RESULTS 
 
Induction of aberrant crypt foci (ACF) formation in DNA polymerase β 
haploinsufficient mice in response to dimethyl hydrazine (DMH)- The purpose of 
this study was to determine the impact of BER deficiency on colon 
carcinogenesis in an animal model. In the first series of experiment, we 
 
determined the impact of β-pol heterozygosity on the development and 
progression of ACF in DNA polymerase β heterozygous knockout mice of 
C57BL/6 background, characterized previously by our laboratory (122). We have 
previously observed a deficiency in β-pol gene expression in various tissues of β- 
 
pol+/- mice (brain, liver, spleen and testes) with a concurrent decline in BER 
capacity (122). As shown in Figure 1A, in this study we have confirmed similar 
 
decline in expression of β-pol gene in the colon mucosa of the β-pol+/- mice 
suggesting a parallel decline in BER activity in the colon of these mice. 
 
It is well established that carcinogen-induced ACF are early indicators of 
initiation of colon cancer in animal models (92, 123, 124). In this study, we 
utilized 1,2-dimethylhydrazine (DMH), an established colon and liver carcinogen. 
It is proposed that DMH converts to the active metabolites azoxymethane and 
methylazoxymethanol in the liver, which are then transported to the colon via 
blood and bile (125). DMH in these tissues exerts its damage to DNA by 
induction of alkylation damage (O6-meG and N7-meG) as well as oxidative 
 
damage. We have previously demonstrated that the β-pol+/- mouse is not 
sensitive to the O6-meG lesion (removed by direct reversal), but is sensitive to 
the N7-meG lesion processed by BER pathway (126). Additionally, we have 
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observed increased accumulation of DNA single strand breaks in the β-pol+/-
mouse in response to oxidative stress, as compared to its wildtype counterpart 
(60). Thus, we postulated that β-pol haploinsufficiency may predispose animals 
to increased colon carcinogenicity and induce development of ACF in response 
to DMH. At the outset of the current study, mice were injected with 30 mg/kg 
body weight DMH for 6 weeks to induce ACF. Six weeks after the final injection, 
the mice were sacrificed and the level of ACF in colon was determined. As 
shown in Fig. 1B, wildtype and β-pol haploinsufficient untreated mice did not 
display any ACF in their colon. Thus, β-pol haploinsufficiency and subsequent 
deficiency in BER capacity is not enough to induce ACF in mice, suggesting that 
β-pol is a low-penetrance gene, requiring a high penetrance environmental insult, 
e.g., DMH or nutritional deficiency, for the damage to accumulate. Furthermore, 
 
as shown in Fig. 1B, β-pol +/- DMH-treated mice exhibited a significantly higher 
level of ACF formation (67% higher) as compared to wildtype counterparts 
 
(15.4±1.8  versus  29.7±1.4,  for  wildtype  and  β-pol+/-  mice,  respectively,  p<0.01). 
 
These  findings  indicate  that  β-pol  haploinsufficient  mice  are  more  sensitive  to 
 
DMH, i.e., β-pol+/- animals show an inability to respond to oxidative stress and 
alkylation damage as compared to their wildtype littermates. Interestingly, no 
significant differences in ACF size and aberrant crypts per focus were observed 
in these animals. Having confirmed these findings, we were interested in the 
effect of folate deficiency in a BER deficient environment on the response to 
 
DMH. 
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Impact of folate deficiency and β-pol haploinsufficiency on ACF formation 
in colon- Folate deficiency has been suggested to impact SAM/SAH ratio (126), 
increase uracil incorporation into DNA (a substrate for BER pathway) and induce 
oxidative stress in animals. Subsequently, to elicit the role of folate deficiency on 
 
ACF formation in wildtype and β-pol+/- animals, animals were fed either a folate 
adequate (FA, 2 mg/kg folic acid) or folate deficient (FD, 0 mg/kg folic acid) diets 
as outlined in Figure 2A. To induce severe folate deficiency, 1% Succinyl 
 
Sulfathiazole was added to the diet deficient in folic acid to prevent synthesis of 
folic acid in the gut by bacteria. The animals’ food intake and body weight were 
monitored weekly. Folate deficiency did not affect body weight while it reduced 
the plasma folate level by 90% as determined by a SimulTRAC-SNB radioassay 
kit  for  vitamin  B12   (57Co)  and  folate  (125I)  per  the  manufacturer's protocol  (ICN 
 
Diagnostics,  Orangeburg,  NY)  as  described previously (80).   After one week  on 
 
respective diet, the wildtype and β-pol+/- mice were injected with DMH once per 
week for 6 weeks (Figure 2A). Six weeks after the final injection DMH-treated 
and control mice were sacrificed and the levels of ACF in colons were 
determined. Interestingly, no ACF was observed in control mice fed a folate 
adequate and/or folate deficient diet. Thus, β-pol haploinsufficiency in 
conjunction with folate deficiency was not enough to induce ACF formation in 
untreated mice. However, DMH-induced ACF were observed in all DMH-treated 
animals. As observed by other laboratories (127, 128), folate deficiency resulted 
in a significant increase in ACF formation in wildtype animals treated with DMH 
as compared to the FA counterpart (15.4±1.8 versus 37.6±5.2, for FA and FD 
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mice, respectively, p<0.01), i.e., folate deficiency predisposes mice to increased 
colon carcinogenesis in response to DMH. As shown in Figure 2B, DMH-induced 
ACF was confirmed and significantly higher in FA β-pol+/- mice as compared to 
their wildtype littermates. Based on these findings and in view of the fact that FD 
resulted in further decline in β-pol expression in colon mucosa (Figure 3), we 
anticipated that β-pol haploinsufficient mice would display a dramatic 
development of ACF when folate is deficient. However, we observed a 
 
significant reduction in the formation of ACF in β-pol+/- mice when compared to 
their wildtype counterparts in a folate deficient environment (50% reduction; 
 
37.6±5.2 versus 18.3±4.1, for wildtype and β-pol+/- mice fed a folate deficient 
diet, respectively, p<0.01, Figure 2B). It has been proposed that the size of ACF 
and number of aberrant crypts per focus could be a more appropriate indicator of 
colon tumorigenesis. As shown in Figure 2C, no significant differences in the 
number of aberrant crypts per focus were observed in all experimental groups 
treated with DMH. These data indicate that β-pol haploinsufficiency attenuate 
carcinogen-induced ACF development when folate is deficient. 
 
To determine whether prolonged folate deficiency increases ACF 
progression or results in ACF regression, wildtype mice were maintained on their 
specific diets for 40 weeks post DMH treatment. After sacrifice, colons were 
macroscopically examined for the development of ACF and the number of 
aberrant crypts per focus (Figure 4A). As shown in Figure 4B, as has been 
reported elsewhere, there was a lack of further increase in ACF numbers, but 
rather a regression of ACFs as well as, a further development to larger ACF with 
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increased aberrant crypts per focus in these mice. Although we observed no 
significant change in crypt multiplicity at 6 weeks post treatment for any group 
studied, the number of crypts per focus significantly increased in FD mice as 
compared to their FA counterparts after 40 weeks in wildtype mice (7.63±0.4 
verses 6.33±0.4, for FD and FA mice, respectively, p<0.05). Moreover, ACF in 
 
FD mice displayed a well defined elevation above the surrounding mucosa 
compared to its FA counterpart which appeared flat (Fig. 4A, Panels IV). Thus 
based on the notion that the size of ACF and the number of aberrant crypts per 
focus are better indicator of tumor formation, folate deficiency does not only 
increase the number of ACF in response to DMH early on, but its adverse impact 
persist resulting in further development of aberrant foci and formation of 
microscopic adenoma, while this phenomenon could be hampered where β-pol is 
deficient. Accordingly, it was important to evaluate the experimental groups for 
tumor analysis. Determining tumor incidents in these mice is important as these 
data potentially shed light on the impact of BER deficiency on colon tumors in a 
folate deficient environment, and determine potential continuity between ACF 
development and formation and metastasis of tumors. 
 
Analysis of pathology in β pol haploinsufficiency and wildtype counterparts 
in response to folate deficiency and DMH treatment- Having established the 
 
DMH-induction of ACF in colon of β-pol+/- mice and their wildtype counter parts 
fed a FA and/or FD diet, we studied the impact of folate deficiency and DMH 
treatment on tumor formation in these animals, based on the known impact of 
DMH on colon and liver tissues. In this study, we followed animals for 40 weeks 
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after the last DMH treatment, to determine the incidence of tumor formation as 
outlined in Figure 5A. Analysis of formalin-fixed and methylene blue stained 
colons provided evidence of advanced ACF in the colon of wildtype FD (Figure 4, 
IV) mice treated with DMH as compared to FA mice (Figure 4, III). In other words, 
while a more defined elevation above the surrounding mucosa was observed in 
ACFs of FD fed mice, the FA mice displayed less developed ACF. Upon 
dissection of animals, we perceived gross changes in the pathology of the 
 
liver in FD DMH-treated mice (50% tumor formation) and FA DMH-treated β-
pol+/-(100% tumor formation). As shown in Figure 5B, panels II and III, the 
 
architecture of the liver tissue in all the FD WT and β-pol+/- fed a FA diet, 
demonstrated an atypical morphology depicting progression of tumors. In 
contrast, there were no visible changes in the liver for wildtype mice consuming a 
 
FA diet and β-pol+/- animals fed a FD diet. Taken together, FD WT and β-pol+/-
fed a FA diet with DMH treatment show more developed ACF and tumor 
 
formation than FA WT DMH-treated and FD β-pol+/- animals. This is suggestive, 
yet again, of haploinsufficiency conferring protection when exposed to 
oxidative/alkylation stress induced by DMH treatment in a folate deficient 
environment. Based on these data, it is inviting to suggest that β-pol 
haploinsufficiency in combination with folate deficiency might impact cell cycle 
arrest and apoptosis in response to DMH, thus impacting ACF development and 
consequent tumor formation. Accordingly, we wanted to determine the impact of 
β-pol haploinsufficiency and folate deficiency on gene expression in mucosal 
tissue of the colon. 
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Effects  of  folate  deficiency  on  gene  expression  in  colon  mucosal  cells- 
 
Having  seen  a  difference  in  colon  pathology,  as  aforementioned,  we  wanted  to 
 
determine differential expression of genes in colon tissues of β-pol+/- mice 
subjected to DMH in a folate deficient environment. In order to ascertain possible 
mechanisms of reduced ACF and tumor formation, we decided to 
 
conduct a microarray analyses on FD β-pol+/- DMH-treated and FD WT DMH-
treated colon mucosa, relative to FA WT. As depicted in the scatter plots of 
differentially expressed genes, there was a marked difference in expression of 
many genes in DMH treated β-pol haploinsufficient mice subject to a folate 
 
deficient environment (4621 upregulated, 5757 downregulated in FD β-pol+/-
DMH-treated versus 528 upregulated, 557 downregulated in FD WT mice) (Figure 
6A). In other words, β-pol haploinsufficiency and DMH-treatment resulted in more 
extensive differential expression of genes as compared to wildtype untreated 
mice. To authenticate the outcome of microarray analysis, we performed 
quantitative RT-PCR using FullVelocity™ SYBR ® Green QRT-PCR 
 
Reagents (Stratagene) on candidate genes depicted as differentially expressed 
through microarray analysis. The candidate genes studied included UNG, MPG, 
 
β-pol, XRCC1, ligase 3 and RAD51li. qRT-PCR results for the 6 genes selected 
were consistent with microarray data. All were significantly downregulated in the 
 
FD β-pol +/- DMH-treated mice (p<0.05) (Table IV). Having confirmed the validity 
of microarray findings, we wanted to identify the inter-relationships that existed 
between the abundance of differentially expressed genes. 
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Based on our assessment of a possible role of DNA repair and apoptosis 
we used DAVID biological function to determine the changes in individual gene 
expression related to these two pathways. Once identified, we generated a series 
of hierarchal clustered heatmaps based on intensity of gene expression from raw 
data files (Figure 6B). Hierarchal clustering assisted in exploring the relationships 
that exist amongst the statistical data identified in the microarray analysis. Here 
we show that upon conducting a clustered analysis, all the data demonstrates a 
thrust toward a reduction in DNA repair and an upregulation in 
 
apoptotic related gene activity in the FD β-pol +/- DMH-treated mucosal tissue. In 
contrast, WT-untreated counterparts had a propensity toward either no difference 
in or slight upregulation in DNA repair and a downregulation in proapoptotic gene 
expression. Furthermore, FD WT DMH-treated groups showed either no 
difference or an upregulation in DNA repair capacity and an upregulation in 
apoptotic. 
 
To further characterize the differences in gene expression, we input 
differentially expressed genes, from the raw data files, into Directed acyclic 
 
Graphs (DAG) view of Gene ontology to acquire clusters of statistically (p<0.01) 
enriched differentially expressed genes according to their gene ontology. In this 
analysis, all gene names from raw data files were input into GOTM without 
reference to significance or intensity levels. Here, again, even with limited data 
input, we confirmed enrichment in DNA repair response and apoptotic activity FD 
 
β-pol β-pol+/- DMH-treated. As shown in Figure 7, the ontology groups enriched 
at program cell death and apoptosis, as well as, in BER, NER and recombination 
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repair all converging on DNA damage response, signal transduction and 
induction of apoptosis. 
 
Analyzing expression data with DAVID biological processes highlighted 
several genes related to promotion of apoptosis and DNA repair activity (Table II, 
III, IV).  Interestingly, we observed a distinct decline in overall DNA repair activity, 
 
including but not exclusive to BER (UNG, Apex, and β-pol), mismatch repair 
(MSH2 and MSH3), and nucleotide excision repair (ERCC2 and Xpc) (Table I). 
In  addition,  we  see  a  downregulation  in  FRAP1  (mediates  cellular  response  to 
 
DNA damage) in β-pol haploinsufficient and FD WT mice, with no change in 
gene expression in FD WT DMH-treated colonic mucosa. In contrast, there was 
an enhanced expression of several proapoptotic genes, including genes involved 
in intrinsic/extrinsic apoptotic pathways (CASP 4 and CASP8), TNF signaling 
 
(Tnfsf12 and Tnfrsf26), as well as, GAS1 and Trp63 (Table II). All of these data 
suggest enhanced programmed cell death, either based on enhanced apoptotic 
activity, forgoing DNA repair, or lack of response of DNA repair pathways to 
cellular damage, increasing the sensitivity of apoptotic related pathways. 
Interestingly, the differential expression of genes in the WT FD DMH-treated 
colonic mucosa was either not differentially expressed or upregulated for DNA 
repair, with the exception of β-pol and upregulated in apoptosis, apart from a 
downregulation in CASP 3. In addition, FD WT colonic mucosa were either not 
differentially expressed or for the most part, slightly upregulated for DNA repair 
and showed reduction in apoptotic activity suggesting that in addition to folate 
deficiency, a compromised BER pathway is required to trigger apoptosis in DMH- 
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treated mice. In view of these findings, we wanted to further confirm these results 
through a series of immunohistological experiments. 
 
Evaluation  of  apoptotic  and  proliferative  activity  in  colonic  mucosal  cells- 
 
Having determined the impact of β-pol haploinsufficiency on colon and liver 
tissue; we wanted to establish why BER insufficiency attenuates development of 
lesions in the face of deleterious surroundings of DMH-induced carcinogenesis 
and folate deficiency. We, therefore, conducted both apoptotic and proliferative 
assays because maintenance of mucosal integrity is reliant on the regulation of 
these two entities, i.e., development of ACF may arise if this integrity becomes 
compromised. To determine apoptotic activity in our experimental groups, we 
measured apoptosis in colon using the TUNEL assay. Firstly, folate deficiency 
increased apoptotic body in wildtype animals (data not shown). Interestingly, 
folate deficiency induced a greater level of apoptotic activity in β-pol 
haploinsufficient mice as compared to wildtype counterparts (Figure 8A, IV). 
 
Next, to characterize the effect of β-pol heterozygosity and folate deficiency on 
cell proliferation in response to DMH treatment, we examined the proliferative 
activity of colon tissues examining BrdU incorporation. As shown in Figure 8D, I, 
 
FA  β-pol+/- 
 
compared 
differential 
 
mice  showed  significantly  more  proliferation  (BrdU  incorporation)  as 
 
to FD β-pol+/- mice. Thus, the TUNEL and BrdU assays confirmed the 
expression observed in microarray analysis, suggesting that folate 
deficiency provide protection against tumorigenesis in DMH-treated β−pol+/- mice 
by altering the balance between DNA repair and apoptotic pathway favoring 
apoptosis. 
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Fig 1. Impact of β-pol heterozygosity on expression of β-pol in colon mucosa and ACF formation 
in colon of mice treated with DMH. (A) Analysis of β-pol expression, mRNA and Protein levels, 
in mucosa from wildtype and β-pol haploinsufficient mice. Expression of β-pol gene was 
determined using a real time PCR technique and the level was normalized base on GAPDH 
expression. Protein level was quantified using a western blot analysis and normalized based on 
the Lamin b protein level. (B) Wildtype (WT) mice and β-pol haploinsufficient mice received 
either no treatment (controls) or i.p. treatment with DMH for 6 weeks at 30 mg/kg body weight 
(DMH treated). Colons were processed after CO2 asphyxiation of mice as described in materials 
 
and methods. Colons were analyzed under light microscopy to visualize the number of ACF per 
mouse colon (ACF/mouse). Bars, SE, * , P<0.01. 
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Figure 2 
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Fig 2. Panel A: Experimental Design: WT and β-pol+/- mice were fed either a folate adequate (2 
mg/kg, FA) or a folate deficient (0 mg/kg, FD) diet for 12 weeks. After one week of ingestion of 
respective diets, mice were injected with 30 mg/kg body weight DMH for 6 weeks. Six weeks 
after final injection, animals were sacrificed by CO2 asphyxiation. Panel B and C: ACF 
 
formation and crypt multiplicity in colon of β-pol+/- mice consuming a folate deficient diet. WT 
and β-pol+/- received either a FA diet or FD diet and subjected to either no treatment (control) or 
i.p. treatment with DMH for 6 weeks at 30 mg/kg body weight (DMH treated). After sacrifice 
colons were processed as per materials and methods. Colons were analyzed under light 
microscopy to visualize the number of ACF per mouse colon (ACF/mouse) (B) and the number 
of crypts per focus (C). Bars with different letters indicate significant differences at P < 0.05. 
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Figure  3 
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Fig 3.   Impact of folate deficiency and DMH treatment on expression of β-pol in colon mucosa of 
 
β-pol+/- mice. Expression of β-pol gene was determined using a real time PCR technique and the 
level was normalized base on GAPDH expression as described in materials and methods. Bars 
with different letters indicate significant differences at p < 0.01. 
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Figure 4 
 
A 
 
I III  
  
10X 10X  
 
 
II IV  
  
10X 10X  
 
 
 
B 
 
 
AC
F/
M
o
u
se
 
 
 
 
  
b 
   
 
40       
 
30 
     b 
 
      
 
20 a     a     
        
 
10 
           
           
 
0 
           
 
FA FD 
 
FA FD 
 
  
 
      
  6 weeks post  40 weeks post 
 
  
treatment 
  
treatment 
 
C 
    
c  
 
8 
   
 
   
b 
 
 
     
 
 6     
 
 4     
 
Ab
er
r
an
t 
s / f o c u s 
    
 
 
a a 
  
 
 
2 
  
 
 0     
 
  
FA FD FA FD 
 
 
6 weeks post 40 weeks post 
treatment treatment 
53 
 
 
 
 
 
 
 
 
 
 
Fig 4. Impact of long term feeding on ACF formation and Crypts Multiplicity. Comparison of 
ACF formation and crypt multiplicity in mice fed either a FA or FD diet at 6 weeks versus 40 
weeks post DMH treatment. Panel A: (I) Normal colonic crypts, (II) ACF formation in FD 
environment 6 weeks post DMH, (III) ACF formation in mice fed FA diet 40 weeks post DMH, 
and (IV) number of ACF of mice fed a FD diet 40 weeks post DMH treatment. Arrows depict 
area of aberrant crypt formation. Panel B: Relative number of ACF/mouse in mice fed either a 
FA or FD diet 6 weeks or 40 weeks post DMH treatment, respectively. Panel C: Number of 
aberrant crypts per focus in mice fed either a FA or FD diet 6 weeks or 40 weeks post DMH 
treatment, respectively. Bars with different letters indicate significant differences at P < 0.05. 
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Figure 5 
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Fig 5.   Impact  of  β-pol+/-  and  folate  deficiency  on  induction  of  tumors  in  DMH-treated  mice.   A. 
 
Feeding study was conducted as depicted in Figure 2. The mice were sacrificed 40 weeks after last 
treatment by CO2 asphyxiation and incidence of tumor progression was assessed. B. 
 
Exemplary H&E micrographs showing tumor formation in liver sections from (I) WT FA (II) 
WT FD, (III) FA β-pol+/- and (IV) FD β-pol+/- mice treated with DMH. The % value represents 
the percent of mice with visible liver tumor formation. All wildtype animals fed the FD diet 
showed liver tumors through H&E analysis. 
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Figure 6 
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Fig 6. Scatter plot of differentially expressed genes and heat map representation of microarray 
data for proapoptotic and DNA repair differentially expressed genes. A. Scatter plot of 
differentially expressed genes from colon mucosa from FD β-pol+/- relative to FA β-pol+/- tissues 
and WT FD relative to WT FA tissues included in the Agilent Whole Mouse Genome 
oligonucleotide micorarray containing probes for over 41,000 well characterized genes. B. 
Hierarchal Clustering analysis was performed using GeneSpringGX V10 (Agilent Technologies) 
software, and the parameters were set for centroid linkage which calculates the euclidean distance 
between the respective centroids of two clusters. A heat map in quadruple (A, B, C, and D) for 
each condition representing proapoptotic and DNA repair genes are shown. 
57 
     
 
Figure 7      
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Fig  7.   DAG  view  of  gene  ontology  analysis,  of  colonic  mucosal  tissue  in  FD  β-pol+/-   versus  FA 
 
WT. Blue boxes indicate enrichment of expression of genes related to DNA repair. Red boxes 
indicate enrichment of expression of genes related to apoptosis. 
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Figure 8 
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Fig 8. Impact of β-pol+/- and folate deficiency on apoptotic activity and induction of proliferation 
in colonocytes. A. Representative photomicrographs showing TUNEL-positive staining in cells 
(brown) of colonic mucosa. (I) WT FA, (II) WT FD, (III) FA β-pol+/- and (IV) FD β-pol+/- mice 
treated with DMH. B. Tally of the TUNEL-positive apoptotic cells. WT and β-pol+/- were fed 
either a FA or FD diet and subjected to DMH treatment. Colon tissue was processed, TUNEL 
assay conducted and percent apoptotic cells were calculated as described in methods. Means 
without a common letter differ, P < 0.01. C. Representative photomicrographs showing H&E of 
colonic mucosa. (I) FA β-pol+/- and (II) FD β-pol+/- mice treated with DMH. Representative 
micrographs showing BrdU staining (brown) of colonic mucosa. (III) FA β-pol+/- and (IV) FD β-
pol+/- mice treated with DMH. Proliferation Analysis: β-pol haploinsufficient mice were treated 
as described in materials and methods. Briefly, 2 hours prior to sacrifice mice were injected i.p. 
with BrdU (2.16mg/kg body weight). Colon segments were fixed in 10% formalin and embedded 
in paraffin. BrdU incorporation was detected by immunostaining as described in materials and 
methods. D. Enumeration of positive proliferation. Percent cell proliferation was conducted as 
detailed in materials and methods. * indicate differences at P<0.01. 
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Gene Sense Primer Sequences Antisense Primer Sequences 
 
   
 
UNG 5’-AACAGGCTTGGTTGGCGAAGG-3’ 5’- CGGCTGGCATCCTAAGACATC-3’  
 
 
   
 
ββ-pol 5’-TACGACCAGAGGCATACAGGGACT-3’ 5’-ACCAACTGGGACGACATGGAGAAG-3’  
 
 
   
 
Lig3 5’-AAGTTCGCATTCAGGTCTAAGC-3’ 5’-AGAGGCTCACAAGTTCCATCC-3’  
 
 
   
 
MPG 5’-GGAGACTGAGGCATACTTGG-3’ 5’-GACTAGAGACATTCAAGCAGA-3’  
 
 
   
 
Rad51l1 5’-ATCTCTCACCGGCATTCCTGTCTACTACCC-3’ 5’-CCGCCATCTCAACCAGTCTCTCAGCAG-3’  
 
 
   
 
GAPDH 5’-GCCAGCACGCAAAAGGTCACATTGT-3’ 5’-AGTTCCGGAAAGCACAGCCAGGATG-3’  
 
 
   
 
 
Table I: Primer Sequences for Real-Time PCR 
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Table II. Summary of the effect of folate deficiency on DNA repair pathway genes in wildtype, 
wildtypeDMH-treated and β-pol+/- DMH-treated mice* 
 
  
WT    WT    B-POL+/- 
 
Accession no.   Gene name - DMH  DMH  
   
 
NM_009764 Breast Cancer 1 -1.7 ns ns 
 
NM_009765 Breast Cancer 2 -1.6 1.4 1.5 
 
NM_178309 BRCA1 interacting protein C-terminal helicase 1 -1.8 ns ns 
 
AF236887 Ataxia telangiectasia and Rad3 related -1.3 1.2 ns 
 
AK048970 Ataxia telangiectasia mutated homolog (human) -1.6 ns ns 
 
NM_021385 RAD18 homolog -1.7 ns ns 
 
NM_011236 RAD52 homolog (S. cerevisiae) ns 1.4 1.2 
 
NM_009015 RAD54 like -2.0 ns ns 
 
NM_011234 RAD51 homolog -1.7 ns 1.6 
 
NM_009013 RAD51 associated protein 1 -1.9 1.4 2.0 
 
NM_009014 RAD51-like 1 -2.4 ns 1.3 
 
NM_011677 Uracil DNA glycosylase -1.6 ns ns 
 
NM_133250 MutY homolog (E. coli) -1.5 ns ns 
 
NM_181569 N-methylpurine-DNA glycosylase -1.4 ns ns 
 
NM_009687 Apurinic/apyrimidinic endonuclease 1 -1.7 ns 1.4 
 
AK047252 Polymerase (DNA directed), beta -1.5 ns ns 
 
NM_021498 Polymerase (DNA directed), epsilon 3 (p17 subunit) -1.3 ns ns 
 
NM_010715 Ligase I, DNA, ATP-dependent -1.3 ns 1.5 
 
NM_010716 Ligase III, DNA, ATP-dependent -1.3 ns ns 
 
AK048442 Ligase IV, ATP-dependent -1.4 ns ns 
 
NM_008628 MutS homolog 2 -1.5 ns ns 
 
NM_010829 MutS homolog 3 -1.4 ns ns 
 
NM_013600 MutS homolog 5 -1.8 ns ns 
 
NM_146235 Excision repair cross-complementing complementation group 6 - Like -2.0 ns 1.8 
 
NM_007949 Excision repair cross-complementing complementation group 2 -1.3 ns ns 
 
NM_009531 Xeroderma pigmentosum, complementation group C -1.4 ns ns 
 
NM_016925 Fanconi anemia, complementation group A -1.4 1.4 ns 
 
NM_175027 Fanconi anemia, complementation group B -1.6 ns ns 
 
NM_007985 Fanconi anemia, complementation group C -1.3 ns ns 
 
NM_178912 Fanconi anemia, complementation group M -1.4 ns ns 
 
NM_018736 Meiotic recombination 11 homolog A -1.3 ns ns 
 
NM_011045 Proliferating cell nuclear antigen -1.3 ns ns 
 
NM_009532 X-ray repair complementing defective repair in Chinese hamster cells 1 -1.2 ns ns 
 
NM_028875 X-ray repair complementing defective repair in Chinese hamster cells 3 -1.7 ns ns 
 
NM_009533 X-ray repair complementing defective repair in Chinese hamster cells 5 -1.4 ns ns 
 
NM_010247 X-ray repair complementing defective repair in Chinese hamster cells 6 -1.5 ns ns 
 
* P<0.01; ns, no significant difference    
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Table III. Summary of the effect of folate deficiency on apoptotic pathway genes in wildtype, 
wildtypeDMH-treated and β-pol+/- DMH-treated mice* 
 
  WT WT B-POL+/- 
 
Accession no. Gene name - DMH DMH  
    
 
NM_008086 Growth arrest specific 1 8.8 ns ns 
 
NM_011641 Transformation related protein 63 27.4 ns ns 
 
NM_009367 Transforming growth factor, beta 2 11.4 ns ns 
 
NM_008337 Interferon gamma 6.2 ns ns 
 
NM_008329 Interferon activated gene 203 5.2 ns 2.1 
 
 
NM_009812 Caspase 8 1.4 ns ns 
 
NM_007609 Caspase 4, apoptosis-related cysteine peptidase 2.1 ns 1.5 
 
 
XM_139295 Caspase recruitment domain family, member 6 1.4 ns ns 
 
NM_175362 Caspase recruitment domain family, member 11 3.6 ns ns 
 
NM_011817 Growth arrest and DNA-damage-inducible 45 gamma 1.5 ns ns 
 
AK010701 Death effector domain-containing DNA binding protein 2 1.6 ns ns 
 
NM_025858 Scotin gene 1.5 ns ns 
 
NM_013693 Tumor necrosis factor 3.9 ns ns 
 
NM_010177 Fas ligand (TNF superfamily, member 6) 2.1 ns ns 
 
 
Mus   musculus  tumor   necrosis  factor   (ligand)   superfamily, 
    
 
NM_009425 member 10 2.0 ns ns 
 
NM_011614 Tumor necrosis factor (ligand) superfamily, member 12 2.2 ns ns 
 
NM_178589 Tumor necrosis factor receptor superfamily, member 21 1.4 ns ns 
 
 
Mus  musculus  tumor  necrosis  factor  receptor  superfamily, 
    
 
NM_175649 member 26 4.1 ns ns 
 
NM_183322 Nur77 downstream gene 1 2.5 ns 3.8 
 
 
NM_009810 Caspase 3 ns ns -1.4 
 
 
NM_134111 ELL associated factor 2 2.6 ns ns 
 
     
 
* P<0.01; ns, no significant difference     
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Table IV. Summary of the effect of folate deficiency on antiapoptotic pathway genes in wildtype, 
wildtypeDMH-treated and β-pol+/- DMH-treated mice* 
 
  
WT WT ββ-pol+/- 
 
Accession no. Gene name - DMH DMH  
   
 
NM_134138 Tumor    necrosis    factor    superfamily,     member    5-induced -1.4 ns 1.3 
 
 
protein 1 
   
 
AK046479 Apoptosis, caspase activation inhibitor -1.7 ns ns 
 
NM_172729 Caspase recruitment domain 4 -1.4 ns ns 
 
AK018453 Transforming  growth  factor,  beta  receptor  associated  protein -1.6 ns ns 
 
 
1 
   
 
NM_009743 Bcl2-like 1 -1.4 ns ns 
 
AK041357 BCL2-like 12 (proline rich) -1.3 1.8 ns 
 
NM_009736 Bcl2-associated athanogene 1 -1.2 ns ns 
 
AJ250687 Bcl2-associated athanogene 3 -2.8 ns ns 
 
BC027637 Transmembrane BAX inhibitor motif containing 4 -1.3 ns ns 
 
NM_009689 Baculoviral IAP repeat-containing 5 -2.8 ns ns 
 
NM_007891 E2F transcription factor 1 -2.0 ns ns 
 
NM_134092 Mdm2,   transformed   3T3   cell   double   minute   p53   binding -1.5 1.3 1.6 
 
 
protein 
   
 
BC043920 FK506 binding protein 12-rapamycin associated protein 1 -1.8 ns ns 
 
* P<0.01; ns, no significant difference    
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Table V. Confirmation of differences observed in Gene Array using real-time PCR for the effect of folate 
deficiency on DMH-treated knockout mice* 
 
 
Accession no. Gene name Array Realtime  
 PCR  
   
 
AK047252 Polymerase (DNA directed), beta -1.5 -1.8 
 
NM_011677 Uracil DNA glycosylase -1.6 -1.9 
 
NM_181569 N-methylpurine-DNA glycosylase -1.4 -1.3 
 
NM_010716 Ligase III, DNA -1.4 -7.0 
 
NM_009014 RAD51-like 1 -2.4 -4.4 
 
* P<0.01    
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DISCUSSION 
 
 
In this study we examined the impact of BER deficiency on colon 
carcinogenesis in a mouse model. BER processes endogenous damage, as 
such, our interest has been in developing model systems to test the processing of 
endogenous damage and determine the impact of BER deficiency on 
tumorigenesis in vivo. Our laboratory has previously characterized DNA 
polymerase β heterozygous knockout mice displaying haploinsufficiency in β-pol 
gene expression in various tissues (Brain, Liver, spleen and testes) with a 
concurrent decline in BER capacity (122). These animals exhibit an accumulation 
of spontaneously arising single strand breaks and chromosomal aberrations with 
age (60). Additionally, in response to alkylating and oxidizing agents, an even 
greater accumulation of single strand breaks and chromosomal aberrations, as 
well as an increase in mutation frequency are observed in these mice (60). In this 
study, we show a significant decline in β-pol expression in the colon of the 
knockout mice as compared to their wildtype littermates, suggesting a BER 
deficiency in the colon of these mice. Using the same animal model, Allen et al. 
(129) showed that normal β-pol activity is necessary for maintaining low germline 
mutation frequency. We previously observed in n β-pol haploinsufficient mice, an 
acceleration of normal, age-related tumors, e.g., lymphomas, developing 
alongside an increased susceptibility to epithelial tumors, e.g., adenocarcinomas, 
which do not typically occur at a high incidence in C57BL/6 mice. Additionally, we 
 
have  shown  that  in  β-pol+/-   mice,  levels  of  single  strand  breaks  accumulate  in 
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response to oxidative stress, to a greater extent than they do in the wildtype mice 
(122). Interestingly, in this study despite compromised BER capacity, the β-pol 
mice do not display any evidence of spontaneously induced preneoplastic lesion 
in their colon confirming β-pol’s low penetrance. Noting this, we wanted to know 
the impact of exposure of animals to DMH, an established inducer of colon and 
liver carcinogenesis. DMH is a DNA damaging agent that induces alkylation 
damage (O6-meG and N7-meG) (130) as well as oxidative damage (131). We 
 
have previously demonstrated that β-pol+/- mice are not sensitive to the O6-meG 
lesion (removed by direct reversal), but is sensitive to the N7-meG lesion 
 
processed by BER pathway (122). Intriguingly, in this study, when the β-pol+/-
mice were treated with DMH a significant increase in ACF formation relative to 
wildtype counterparts were observed. Thus, herein, we have confirmed that the 
β-pol heterozygous mice are predisposed to preneoplastic lesions and cancer 
development, primarily by reducing tolerance to the DNA damage in response to 
DNA damaging agent, DMH. As such, these manipulations gave rise to an animal 
model of colon carcinogenesis for future study. 
 
 
While the mechanism by which folate deficiency increases cancer risk is 
not clear, it has been demonstrated to alter both DNA damage and DNA 
methylation. Folate deficiency has been shown to induce damage repaired via 
BER pathway (80). Based on this fact, we were interested in determining what 
impact folate deficiency would have on a BER deficient model. First, we needed 
to confirm folate deficiency as an inducer of ACF when wildtype mice are 
67 
 
 
subjected to a carcinogenic environment. Others, such as Branda et al. (82) have 
demonstrated that folate deficient animals are less able to repair damages 
induced by alkylating agents. For example, ENU was found to be more 
mutagenic within the context of folate deficiency. Interestingly, folate deficiency 
did not enhance the mutagenic effect of cyclophosphamide suggesting a lack of 
sensitivity to lesions repaired by the nucleotide excision repair pathway. As well, 
Duthie et al. (85) have further shown that human colon epithelial cells grown in 
the absence of folate are poorly able to repair damages induced by MMS (an 
alkylating agent) and hydrogen peroxide (an oxidizing agent). Growth in a low 
folate medium has also been shown to impair excision repair capacity of 
colonocytes (86). More oxidative damage, which is repaired by BER, 
accumulates in response to amyloid β-peptide in neuronal cells depleted of folate 
 
(87). In line with these studies, we show an increased incidence of ACF, 
microscopic adenoma and liver tumor formation in wildtype mice upon DMH 
treatment, when folate is deficient. These data indicate, in conjunction with our 
previous studies (80), that the pathway responsible for repairing these damages 
may be ineffective when folate is limiting. Based on the above findings, it is 
inviting to suggest that folate deficiency mimics BER deficiency perhaps by 
overwhelming the capacity of BER through inhibition of its rate determining 
enzyme, DNA polymerase β. In other words, we suggest that the inability to 
induce β-pol results in a functional BER deficiency, providing a logical 
explanation for the phenotype induced by folate deficiency. That is, if folate 
deficiency exerts its effects by inhibiting BER then the phenotype of folate 
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deficiency should mimic that of BER deficiency, as shown in our previous studies 
 
(80). 
 
To address whether an underlying BER deficiency would exacerbate the 
effects of folate deficiency, we subjected β-pol haploinsufficient mice to folate 
deficiency. We have recently reported that aging and β-pol deficiency interact to 
accelerate the development of malignant lymphomas and adenocarcinoma and 
increases tumor bearing load in mice. We anticipated that folate deficiency and 
BER deficiency will likewise interact to accelerate ACF formation and tumor 
development in β-pol haploinsufficient animals. As expected, folate deficiency 
resulted in a significant increase in ACF formation in wildtype animals exposed to 
DMH, however folate deficiency reduced development of ACF in β-pol 
haploinsufficient mice. Interestingly, prolonged feeding of the folate deficient diet 
resulted in advanced ACF formation, microscopic adenoma and liver tumors in 
wildtype mice, while β-pol haploinsufficiency attenuated onset and progression of 
ACF to microscopic adenoma and prevented liver tumorgenesis. These findings 
are rather exciting because folate deficiency appears to provide protection 
against tumorigenesis in a BER deficient environment in all tissues where DMH 
exert its damage. 
 
To enhance our understanding of the dynamics contributing to a reduction 
in ACF formation and liver tumorogenicity we conducted microarray analyses on 
colon mucosa of β-pol haploinsufficient and wildtype mice in both a folate 
adequate and folate deficient environment. Microarray analysis from our study 
produced a list of up and down regulated genes, which were classified by their 
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gene  ontologies.  The  data  show  a  distinctly  compromised  DNA  repair  capacity 
 
(expression of over 100 genes are downregulated), including, but not restricted to 
 
BER, NER and MMR, in FD β-pol+/- with DMH treatment. As previously 
mentioned, BER is responsible for the removal of endogenous alkylation, 
 
oxidized bases and uracil.  Here we see a decrease in glycosylase, APEX, β-pol, 
 
and ligase activity in FD DMH treated β-pol haploinsufficient mucosal tissue. In 
addition to BER, NER which is responsible for the repair of bulky distortions in 
 
DNA and MMR, which is accountable for the maintenance of normal Watson 
Crick base pairing are also impaired. Findings from FD WT DMH treated mice 
showed a significant upregulation in UNG, APEX, and ligase 1 activity, with a 
significant downregulation in β-pol. These aforementioned findings are in line 
with our previous studies (80), demonstrating FD ability to impair BER capacity. 
 
We were also interested in the FK506 binding protein 12-rapamycin 
associated protein 1 (FRAP1), also known as mTOR, for it is activated in various 
types of neoplastic disease (132), and its inhibition makes cancer cells more 
sensitive to chemotherapeutic agents (133). FRAP1 is a central controller of cell 
proliferation, cell growth, and cell survival, becoming impaired in response to 
DNA damage and nutrient withdrawal (134). Relative to our study, we see that 
either damage as a result of a BER deficiency or deprivation of folate enhances 
cell survival as depicted by increased incidence of ACF and tumor formation. 
Fujishita et al. (135), however, have shown that inhibition of the mTOR pathway 
suppresses the formation of intestinal polyps and death rates in Apc min mice. 
As well, Shen et al. (136), showed in their study utilizing yeast cells, that the 
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inhibition of FRAP1 through TORC1 complex by rapamycin, enhanced the 
sensitivity to MMS treatment, resulting in increased cell death. Interestingly, we 
show a significant downregulation in FRAP1, in FD DMH βpol haploinsufficiency. 
 
These findings are similar to that of Fujishita (135) and Shen (136), although 
here we show FD inhibiting an already BER deficient environment, suggesting a 
likeness of rapamycin inhibiting TORC 1 complex and as such, enhances the 
lethality of DMH. We suggest, therefore, that the downregulation of FRAP1 in the 
FD DMH β-pol haploinsufficient mouse model could account for the reduced 
incidence of ACF and tumor formation. 
 
Observing the lack of response in DNA repair and reduction in FRAP1, we 
studied the expression of apoptotic gene on our microarrays to determine if cell 
death may be responsible for tending of imposed damage and thus reducing the 
level of ACF and tumor formation. Notably, there was an upregulation of 75 
differentially expressed genes related to apoptotic activity. There was an 
upregulation in intrinsic/extrinsic apoptotic, and TNF signaling, as well as cell 
cycle arrest in β-pol haploinsufficient mice. Interestingly, we see a reduction in 
ATM, ATR and CHK2, which phosphorylate p53, rendering it active, however, a 
significant increase in p21 expression, a collective inhibitor of cell cycle 
progression, is detected (137). Both, CASP11, which is tightly regulated at the 
transcription level, and known to regulate both apoptosis and inflammation (138), 
and CASP8, an initiator of apoptosis (139) are elevated in β-pol haploinsufficient 
mice in a folate deficient environment. In addition, we see a highly significant up 
regulation in GAS1, a known tumor suppressor (140, 141) that mediates cell 
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cycle arrest and apoptosis (142, 143, 144, 145). Based on our results, we would 
suggest that colon cells in DMH treated β-pol haploinsufficient mice in a folate 
deficient environment would prefer to undergo cell death, rather than attempt 
repair. Interestingly, a distinct upregulation in PARP 3, 4, 8, 12 and 14 
expression in FD, DMH treated β-pol haploinsufficient colonic mucosa is 
observed. In addition to mediating BER by recruiting BER intermediates like β-
pol, PARPs are the key regulators of cell survival and cell death (146). As well, 
 
Huang et al. (147), in their study utilizing Bax-/-Bak-/- mouse embryonic 
fibroblasts, show depletion in ATP secondary to PARP-1 activation, which in turn 
inhibits FRAP1. We suggest that down regulation in expression of key enzymes 
in BER pathway, e.g., UNG, β-pol and APE1, Lig1 and XRCC1, renders available 
PARPs futile. In other words, elevation in PARPS would result in depletion of 
ATP/NAD(+) levels and subsequent down regulation in FRAP1/mTOR pathway. 
 
Moreover, cleavage of PARPs by CASP3 (148) triggers apoptosis and induces 
cell death. Interestingly, while FD WT DMH treated animals show a significant 
decline in the level of CASP3, a key “executioner” of apoptosis (149). It should be 
noted that the activity in FD WT counterparts show either no change in 
differential expression or slight opposing expression of both apoptotic and DNA 
repair genes. These findings provide further evidence of defense by BER 
deficiency in the multi-step process of colon/liver cancer, when folate is deficient. 
 
We propose that β-pol deficiency in a folate deficient environment results 
in increased accumulation of DNA repair intermediates that impacts the balance 
between cell survival and cell death, pushing cells toward apoptosis, thus 
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reducing onset and progression of preneoplastic lesions. In support of this notion, 
we provide evidence that the β-pol haploinsufficient mice fed a folate deficient 
diet display increased apoptotic body and decreased proliferation in their colon in 
response to DMH. Interestingly, in agreement with our findings, 
 
Ochs et al (150) demonstrated that BER deficiency results in the accumulation of 
repair intermediates, along with increased DSB in β-pol null fibroblasts exposed 
to the alkylating agent, MMS. Interestingly, accumulation of DNA damage in 
these cells resulted in decline in Bcl-2 and increased Caspase 3/9 activation 
triggering apoptosis in a replication dependent manner. Moreover, Taverna et al 
 
(151) showed that BER inhibition by methoxyamine increased cytotoxicity of the 
methylating agent temozolomide through persistence in AP sites, increased DSB 
and increased apoptosis in HCT 116 colon cancer cell lines. Likewise, Rinne et 
al. (152) showed that breast cancer cell lines overexpressing N-methylpurine 
 
DNA glycosylase (MPG) exposed to the alkylating agents methyl 
methanesulfonate, N-methyl-N'-nitro-N-nitrosoguanidine, methylnitrosourea, 
dimethyl sulfate, and the clinical chemotherapeutic temozolomide, significantly 
increases the sensitivity of these cells. Sensitivity is further increased through 
coadministration of the BER inhibitor methoxyamine making cells unable to 
complete repair initiated by the glycosylase, and resulting in an increase in the 
number of AP sites and SSBs. Furthermore, Fishel et al. (153) showed that 
overexpression of MPG, in addition to inhibition of BER pathway via 
methoxyamine, dramatically increases the sensitivity of ovarian cancer cells to 
the DNA methylating agent temozolomide via increase in apoptotic activity. In 
73 
 
 
other words, methylation of N7 and O6 positions of guanine and the N3 of adenine by 
temozolomide, in addition to overexpression of MPG, resulted in initiation of 
 
BER. However, inhibition of BER pathway by methoxyamine downstream of 
glycosylase resulted in an accumulation of DNA repair intermediate, increased 
DNA DSB and triggered apoptosis in a p53 independent manner. Furthermore, 
Trivedi et al. (154) showed that elevated MPG expression in addition to β-pol 
knockdown would result in increased sensitivity of human breast cancer cells to 
temozolomide. Interestingly, Trivedi et al (154) showed that overexpression of 
 
β-pol with mutation in its polymerase site, while maintaining it dRP lyase activity, 
resulted in restoration of resistance to temozolomide in β-pol knockdown human 
breast cancer cell lines. 
 
The in vitro studies outlined above utilize specific glycosylases for the 
creation and persistence of abasic sites, while, methoxyamine potentiates the 
cytotoxicity of telozolomide through its binding to abasic sites, hampering BER, 
resulting in accumulation of repair intermediates and ultimately, DNA DSBs. 
These conditions generate a perfect environment for apoptosis to take place. 
These studies add to the fascination of our own, for the aforementioned were 
conducted within cell lines, whereas, our in vivo data demonstrate protection 
against actual onset and progression of tumor, via similar mechanism. Our data 
shows that treatment of mice with DMH results in damage to bases, along with 
upregulation in UNG expression/activity (data not shown), that when combined 
with βpol haploinsufficiency, results in an accumulation of DNA repair 
intermediates and ultimately DNA DSBs, resulting in the onset of ACF, 
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progression of microadenoma and tumors, in colon and liver, respectively. We 
suggest that wildtype animals fed a folate deficient diet and subject to DMH 
treatment exhibit a similar scenario. In other words, folate deficiency and DMH 
treatment would result in the induction of DNA damage, upregulation in specific 
glycosylases, and downregulation in BER capacity all of which contribute to an 
accumulation of repair intermediates that create an environment favoring tumor 
formation. In contrast, BER haploinsufficiency combined with folate deficiency 
provide a protective environment against DMH carcinogenesis. Thus, folate 
deficiency sensitizes the β-pol haploinsufficient mice to DMH, generating even 
higher level of DNA SSBs and DSBs, mimicking the environment observed in in-
vitro studies. These conditions are favorable to apoptosis, where DNA repair 
machineries are downregulated and proapoptotic pathways are induced. 
 
In   line   with   our   findings,   Lawrance   et   al.   (155)   showed   that   folate 
 
deficiency in mthfr deficient Apcmin/+ mice results in a reduction in adenoma 
formation in colon tissue, while an elevation in dUTP/dTTP ratio in DNA and an 
increase in apoptotic activity are observed. APC has been shown to interact with 
β-pol (156). Furthermore, haploinsufficiency in reduced-folate carrier gene 
 
(Rfc
+/-
)  creating a folate  deficiency phenotype  resulted in decreased  adenomas 
 
and tumor load in Apcmin/+ mice. In addition, Branda et al (157) showed folate 
deficiency reduced mutation frequency in 3-methyladenine glycosylase null mice 
exposed to methyl methanesulfonate. The aforementioned, demonstrate much 
the same as our investigation in that modulating BER repair, through β-pol and 
exposure to folate deficiency, results in reduced repair activity while influencing 
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apoptosis. Additionally, research conducted by Duthie et al. (158), demonstrated 
that NCM460 immortalized cells in a folate deficient media exposed to hydrogen 
peroxide exhibit increased apoptotic activity, as well as, decreased proliferation. 
Furthermore, Crott et al. (159) showed an inverse correlation between 
expression of genes involved in cell cycle checkpoint and media folate levels (25 
to 100nM) in NCM460, HCEC and NCM356 cell lines derived from human colon, 
irrespective of oxidative stress. These studies, much like our own, have 
significantly reduced levels of folate, rather than a complete folate deficit. In our 
experiments, despite use of a folate deficient diet and use of succinyl 
sulfathiazole, an 80 – 90% reduction in folate levels is observed relative to folate 
adequate diets. It is at this reduced level that we see protective effects. 
 
In conclusion, our data indicate BER deficiency and DMH treatment 
interact synergistically to increase DNA repair intermediates and genomic 
instability, resulting in formation of preneoplastic lesions, while folate deficiency 
in BER deficient mice exposed to DMH provides protection, creating an 
environment preferential to apoptosis. While folate deficiency induces DNA 
damage in control/untreated mice (80), slight upregulation in DNA repair activity 
and maintaining normal or slightly lower levels of apoptotic activity prevents 
onset of tumorigenesis. In contrast, folate deficiency in response to DNA 
damaging agent would result in accumulation of genotoxic intermediates that are 
potentially mutagenic and thus, as shown here, prone to increased ACF and 
tumor formation. However, when a BER deficiency is present and subject to 
exposure of DMH, induction of a folate deficient environment results in a further 
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reduction of DNA repair capacity and increased level of apoptosis. This is 
suggestive that the damage is so extensive that is beyond repair, thus opting for 
cell death. We surmise that the damage induced blocks BER capacity, resulting 
in elevated PARP levels, which in turn deplete energy availability to the cell, 
signalling need for cell death. These conditions result in a reduction of ACF and 
tumor formation. This study has great therapeutic importance and human 
relevance as recent findings indicate BER inhibitors in combination with the DNA 
methylating agent temozolomide, function as an effective chemopreventive agent 
in colon cancer (160). In addition, these findings have relevant translational 
implications, since variants/polymorphisms in BER has been associated with 
increased cancer risk, and an alteration in micronutrients could potentially 
provide protections under the right conditions. 
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CHAPTER 4 
 
Microarray Gene Expression Profiling of Dietary Folate Deficiency on Colon 
Carcinogenesis in DNA Polymerase ββ Haploinsufficient Mice 
 
Introduction 
 
Colorectal cancer is one of the most prevalent and lethal types of 
malignancies in Western countries and represents the second leading cause of 
cancer death in the US (161). It has been implicated that environmental factors 
relative to a Western lifestyle are responsible for this intestinal neoplastic 
transformation. Much research has focused on the strong connection between 
the carcinogenic properties of folate deficiency and increased colon cancer risk 
 (162). It has been proposed that folate deficiency imparts high levels of uracil and 
oxidative damage to the DNA that may increase the risk of atypical DNA 
methylation, high levels of uracil misincorporation in DNA, and increased levels 
of DNA single strand breaks. Folate has also been shown to increase 
micronucleus formation and chromosomal aberrations all leading to increased 
mutational frequency and colon cancer progression. 
 
It is well documented that the Base Excision Repair (BER) pathway is 
responsible for the removal of uracil and oxidized bases throughout the cell 
cycle. Its primary obligation is believed to be the repair of small, non-helix 
distorted lesions in the DNA. If damaged bases are left unrepaired it could cause 
mutations via mispairing and/or strand breaks in DNA during replication. Briefly, 
the removal of damaged bases by BER involves i) a specific DNA glycosylase 
binding to the affected base and hydrolyzing the N-glycosidic bond, releasing the 
damaged base while keeping the DNA backbone intact. ii) The abasic site is 
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subsequently recognized by an endonuclease, notably Ape 1, which nicks the 
phosphodiester backbone immediately 5’ to the lesion leaving a strand break with 
a normal 3’-hydroxyl group and an abnormal 5’dRp residue. iii) synthesis of new 
DNA by incorporation of the correct nucleotide by DNA polymerase, iv) excision 
of the 5’dRp moiety, and v) ligation by a DNA ligase (Ligase 1 or Ligase 
 
3/XCRR1 (127). Short patch BER is the major repair mode, where β-pol performs 
the polymerization steps and appears to be the rate-limiting step by virtue of its 
dRp lyase activity (53). With the removal of damaged bases, as would occur with 
uracil misincorporation, and repair of abasic sites, a transient formation of a DNA 
single strand break occurs. We have previously shown that 
 
β-pol+/- results in genomic instability as a result of persistence of these DNA 
single strand breaks which could result in DNA double stand breaks (60). 
 
Additionally, in response to alkylating and oxidizing agents, these animals display 
accelerated age-related tumor development such as lymphomas, which are 
atypical of C57BL/mice (77). 
The β-pol haploinsufficient mouse has been shown to have a reduced 
ability to tolerate carcinogen exposure, demonstrating reduced BER capacity and 
this translates into concern regarding the development of certain cancers. In 
 
fact, mutations in the gene encoding β-pol have been previously identified in 
human colorectal, prostate, lung and breast carcinomas (68, 69, 70, 71). These 
mutations are found only in the tumor tissue and not in the adjacent normal 
tissue, thus corresponding to sporadic mutations (73). Based on these findings 
and our previous reports of β-pol haploinsufficiency on DNA (60), it would seem 
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prudent to assume that the high levels of uracil misincorporated into the DNA 
backbone, as a result of inadequate folate levels, would lead to an increase 
insingle strand breaks as a result of β-pol deficiency, overwhelming BER, 
proceeding to mutagenesis. Centered on these experimental findings, in our 
 
study of β-pol+/- in a folate deficient environment, we expected that β-pol 
haploinsufficiency would result in extreme damage with a dramatic increase in 
the formation of the first histologically detectable change apparent in colon 
cancer, the aberrant crypt and potentially progressive colon cancer development. 
Astoundingly, we saw not only significantly less ACF development but 
additionally, those that did form were visually less advanced than wildtype mice 
exposed to 1,2 dimethylhydrazine (DMH) a known colon and liver carcinogen. As 
well, we saw no detectable pathological changes in liver tissue as noted in the 
wildtype folate deficient mice subject to DMH (Figure 5B). Based on our 
remarkable findings, the purpose of this study was to determine the potential 
mechanism behind the protective effect β-pol haploinsufficiency appears to 
confer with respect to colon cancer development in response to folate deficiency 
and DMH. Microarray technology has made accessible a powerful tool for 
identifying possible means of the effect of folate and DMH on the onset and 
progression of colon cancer in the colonic mucosa of β-pol haploinsufficient mice 
at the level of the transcriptome. These findings are invaluable for they offer 
direction, through pinpointing potential means of this disease, necessary for 
further studies. 
 
Methods 
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Animals.   Experiments   were   performed   in   young   4   to   6   month   old 
 
C57BL/6-specific  pathogen  free  male  mice  and  mice  heterozygous  for  the  DNA 
 
polymerase β gene (β-pol+/-) (77). All practices performed on animals were in 
agreement with the National Institutes of Health (NIH) guidelines for the care and 
use of laboratory animals. Mice were backcrossed to the C57BL/6 background. 
 
The Wayne State University Animal Investigation Committee approved the 
animal protocol. Mice were maintained on a 12-h light/dark cycle and given water 
ad libitum. 
 
Diets   and   Carcinogenic   Treatment.      After   acclimation   for   7   days, 
 
wildtype (WT) and β-pol+/- mice were randomly assigned to two dietary groups; a 
folate adequate (FA) or folate deficient (FD) AIN93G-purified isoenergetic diet 
 
(Dyets, Inc., Lehigh Valley, PA) as described previously (80). The FA group 
received a folate adequate diet containing 2 mg/kg folic acid. The FD group 
received a folate-deficient diet containing 0 mg/kg folic acid. Diets were stored at 
–20°C. 1% succinyl sulfathiazole was added to all diets .  One week after 
commencement of food ingestion, randomly selected mice from both FA and FD 
were injected i.p. with 1,2-Dimethylhydrazine HCL (DMH, 30 mg/kg body weight) 
in 10mmol/L of NaHCO3 (Fisher Scientific, Fair Lawn, NJ) once a week for 6 wks 
 (Figure2, panel A). Both food intake and body weights were checked twice 
weekly to monitor for signs of of toxicity, e.g., weight loss, and the diets were 
continued for 12 weeks. 
 
Microarray assays. Total RNAs were isolated from the colon mucosa of 
mice using the RNeasy Mini Kit (Qiagen, Valencia, CA) per manufacturer's 
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protocol.    RNA  samples  were  quantified  with  NanoDrop  ND-1000  (NanoDrop 
 
Technologies, Inc, Wilmington, DE) and 260/280 ratio in the range of 2.0-2.2 was 
defined as acceptable. A quality check of the total RNA was performed using an 
Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). One micro liter of 
total RNA sample was applied on RNA 6000 NanoChip, and the assay was run 
on the Bioanalyzer to determine if the 18S and 28S ribosomal bands are defined 
and to ensure no RNA degradation was present. Optimal concentration used to 
check the RNA quality is 250ng/∝l. 
Microarray expression profiling was conducted by Microarray & 
Bioinformatics Facility Core at Wayne State University (Institute of Environmental 
Health Sciences, Detroit, MI) according to the manufacturer’s protocol. A 
balanced block experimental design was used: 4 microarrays were completed for 
each comparison, with each microarray representing 1 randomly selected labeled 
mucosal sample from each experimental group paired with 1 randomly selected 
 
FA WT labeled mucosal sample i.e. in total 4 mucosal RNA samples from FDWT 
cohybridized with 4 FAWT, 4 FDWT DMH treated cohybridized with 4 FAWT and 
 
4 FD β-pol+/- DMH cohybridized with 4 FAWT treated, representing 4 micorarrays for 
each experimental comparison. Samples on a given array were oppositely labeled 
with Alexa 647 and Alexa 555 dyes. The four microarrays for a given 
 
group (i.e., WT untreated, WT DMH or β-pol+/- DMH treated) represent samples 
from eight separate mice, providing consideration of biological variation. In total, 
 
12 arrays representing 24 mice (8 WT, 8 WT DMH-treated, 8 β-pol+/- DMH-
treated) were completed. Dye swaps were used to account for dye bias effects 
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such that of the four arrays in a given phenotype group, two had FD treated 
samples labeled with Alexa 647 co-hybridized with control samples labeled with 
 
Alexa 555 while the other two arrays within the same phenotype group had 
opposite dye orientations. Microarrays were scanned using the Agilent dual laser 
DNA micorarray scanner model G2565AA, with 10 micron resolution. 
 
Microarray gene profile analysis. Microarray image analysis was 
performed with Agilent Feature Extraction software, version A.5.1.1. Hierarchal 
 
Clustering analysis was performed using GeneSpringGX V10 (Agilent 
Technologies) software, and the parameters were set for centroid linkage which 
calculates the euclidean distance between the respective centroids of two 
clusters. Heatmaps were created by inputting accession numbers of differentially 
 
expressed genes, at p<0.001, for FDWT and FD β-pol+/- DMH-treated 
experimental groups through DAVID functional annotation. Outputs revealed 
gene onotologies of differentially expressed genes, which were than compared to 
created differentially expressed gene lists of DAVID biological processes, such 
as apoptosis and DNA repair. Data sets were then combined for FDWT and FD 
β-pol+/- DMH-treated to 1 large data set in order to create heatmaps for each 
biological function. Gene ontology analysis was performed using Gene Ontology 
 
Tree Machine (GOTM), (Bioinformatics,Vanderbilt University), applying 
differentially expressed genes as depicted in the heatmaps`. We chose a single 
gene set analysis, where GOTM compares the distribution of single gene set in 
each GO category to those in an existing reference gene list from the mouse 
genome, identifying GO categories with statistically significant enriched gene 
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numbers as determined by the hypergeometric test (p<0.01) (119, 120). Real 
time quantitative RT-PCR was used to confirm the data obtained for selected 
genes in DNA repair pathways as described above. 
 
Results 
 
Experimental design 
 
To elicit the role that folate plays in the onset of colon carcinogenesis in a 
 
BER deficient environment, wildtype and β-pol+/- animals were fed either a folate 
adequate (FA, 2 mg/kg folic acid) or a folate deficient (FD, 0 mg/kg folic acid) diet 
as outlined in Figure 2A. To induce severe folate deficiency, 1% Succinyl 
Sulfathiazole was added to the diet deficient in folic acid to prevent synthesis of 
folic acid in the gut by bacteria. The animals’ food intake and body weight were 
monitored weekly. Folate deficiency did not affect body weight while it reduced 
the plasma folate level by 90% as determined by a SimulTRAC-SNB radioassay 
 
kit  for  vitamin  B12   (57Co)  and  folate  (125I)  per  the  manufacturer's protocol  (ICN 
 
Diagnostics, Orangeburg, NY) as described previously (80). After one week on 
respective diet randomly selected mice from each feeding study were injected 
with 30mg/kg body weight DMH once per week for 6 weeks (Figure 2A). We 
chose DMH as it is a known colon and liver carcinogen that gets converted to the 
active metabolites azoxymethane and methylazoxymethanol in the liver, which 
are then transported to the colon via blood and bile (125). Once in the tissues 
 
DMH induces alkylation (O6-meG and N7-meG) as well as oxidative damage 
impairing DNA. Although direct reversal is responsible for the repair of 06-meG, 
we have previously shown that the BER pathway processes N7-meG lesions 
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(60). Six weeks after the final injection DMH-treated and control mice were 
sacrificed. Mucosal scrapings were taken and used to perform a balanced block 
experimental microarray design to screen for differentially expressed genes in 
response to folate deficiency (FD) and 1,2- dimethylhydrazine (DMH) mice. 
 
Microarray gene expression analysis 
 
Our previous studies determined an increased level of ACF, increased cell 
proliferation, as depicted by BrdU analysis and a decrease in apoptotic activity, 
shown by the TUNEL assay, in wildtype mice exposed to DMH in a folate 
 
deficient environment. In contrast, FD DMH β-pol+/- treated mice showed 
decreased formation of ACF, reduced proliferative capacity and an increase in 
the level of apoptosis (163). We wanted to know, therefore, the effect of folate 
and DMH on gene expression. In order to do so, we categorized genes according 
to their biological function as depicted through DAVID biological processes. 
 
 
Gene Expression analysis of folate pathway 
 
 
Knowing folates suggested role in colon carcinogenesis, we initially 
analyzed microarray gene expression data with respect to folate and its 
 
metabolism (Table VI). Here we see a down regulation in N5, N10 methylene 
tetrahydrfolate reductase (MTHFR), an enzyme which reduces 5, 10-
methylenetetrahydrofolate to 5-methyltetrahydrofolate using NAD(P)H as the 
 
reducing agent, in FA DMH, FD DMH treated and FD β-pol+/- DMH treated mice. 
As well, we see an upregulation of dihydrofolate reductase (DHFR), which 
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reduces dihydrofolic acid to tetrahydrofolic acid, using NADPH as electron donor, 
in FDWT, FA DMH, and FD DMH treated colonic mucosa, however it is 
significantly downregulated in FD β-pol+/- DMH treated mice. Interestingly, we 
also see an increase in thymidylate synthase (TS), an enzyme which converts 
dUMP to dTMP, in FD DMH treated animals and no change in FD WT or FA WT 
 
DMH treated mice, whereas FD β-pol+/- DMH treated mice show a significant 
downregulation. Correspondingly, there is a significant downregulation in 
dUTPase (5031412I06Rik) in β-pol haploinsufficiency which is either upregulated 
or not differentially expressed in other animal models. This indicates a lack of 
 
pyrimidine synthesis in FD β-pol+/- with DMH treatment, in contrast to the other 
experimental models which are still capable of producing thymidine. From these 
findings one could conclude that availability of purines and pyrimidines would be 
significantly lowered in the β-pol haploinsufficient mouse when subject to DMH 
and a folate deficit. These results shed light on our previous findings of reduced 
 
DNA repair capacity in FD β-pol+/-  DMH treated mice. 
 
 
Gene Expression analysis of DNA repair genes 
 
Both FD DMH and FA DMH treated mice showed a 75% elevation in DNA 
repair expression (44 upregulated and 15 downregulated, 33 upregulated and 11 
downregulated, respectively), whereas FD untreated animals demonstrated an 
84% elevation (31 upregulated and 6 downregulated) in repair activity. 
Interestingly, FD β-pol+/- DMH treated mice shows an 88% reduction in DNA 
repair activity (13 upregulated and 92 downregulated). These findings indicate 
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sufficient levels of purines and pyrimidines for DNA repair in FDWT, FA DMH, 
and FD DMH treated mice, however, deficiency in these nitrogenous bases 
appears to hamper DNA repair in FD β-pol+/- DMH treated mice. It should be 
noted that genes expressed in any experimental model are characteristically, but 
not exclusively related to BER. NER, MMR NHEJ and recombination repair 
(Table VII). Denoting the reduced capacity in repair, determining repair 
machineries access to chromatin is important, for this access is needed in order 
for repair to proceed. 
 
Gene expression analysis of histones 
 
Noting the differential expression of DNA repair genes in all animal models 
studied, we wanted to know the impact of a BER deficiency on histone 
modification when folate is deficient, for it is the histones that unpackage the 
 
DNA in order for damage recognition. Chromatin remodeling allows for changes 
in histone-DNA interactions in the nucleosome. This is achieved by the action of 
chromatin-remodeling complexes, which are a family of ATP-dependent 
machines that participate in transcriptional regulation, DNA repair, and chromatin 
assembly. (164). Gene expression of these family subunits are significantly 
 
downregulated in FD β-pol+/- DMH treated colonic mucosa, but show no 
differential expression in FD WT, FA WT DMH, and FD WT DMH treated mice 
(Table VIII). Our microarray analysis also shows a significant reduction in genes 
related to histone H2A, one of the core components of the nucleosome, in FD β- 
 
pol+/- DMH treated mice, whereas all other experimental groups showed no 
change in expression of H2A with the exception of one varied gene being 
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downregulated in each of the groups. Of particular interest is H2AX , for it is a 
receptive target for looking at DSBs in the cell. Once phosphorylated, H2AX 
lessens DNA condensation and increasing its availability for recruitment of repair 
machinery to DSBs (165). We have previously ascertained an increase in SSB in 
β-pol haploinsufficiency exposed to a folate deficit (80). If these SSB are not 
properly repaired, they may result in double strand breaks (DSB) in replicating 
 
DNA. DSB recognition involves activation of ATM which functions to control the 
rate at which cells grow. In turn, ATM phosphorylates H2afx. Both ATM (Table 
 
VII) and H2AFX are significantly downregulated in FD β-pol haploinsufficiency 
with i.p DMH treatment. All other experimental groups showed no difference in 
expression of these aforementioned genes. Although phosphorylation of H2AX is 
most dependent on ATM, phosphorylation can also be carried out via ATR 
 
(Table VII) and PRKDC (also known as DNA-pk)(Table VII) (165, 166, 167, 168) 
Both of these aforementioned genes are instrumental in NHEJ and HR, pathways 
that are significantly downregulated in FD β-pol+/- DMH treated mice, whereas 
they are either increased or not significantly different in FD WT, FA WT DMH, 
and FD WT DMH treated mice. These findings are suggestive of chromatin 
condensation an event which would favor apoptotic activity (169). 
 
Gene expression analysis apoptotic activity 
 
Based on our previous findings of apoptotic activity depicted by TUNEL 
assay (Figure 8A), we wanted to know the apoptotic gene expression of all 
experimental models. We saw a 51% upregulation (22 upregulated and 21 
downregulated) in proapoptotic activity in FD DMH treated mice and 57% (69 
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upregulated and 53 downregulated) in FD β-pol+/- treated mice in contrast to FD 
WT untreated (70% reduction, 9 upregulated and 21 downregulated) and FA WT 
DMH treated (49% reduction, 19 upregulated and 20 downregulated). There was 
a 59% decline (15 upregulated and 19 downregulated), 67% decline (9 
upregulated and 18 downregulated), 71% decline (11 upregulated and 27 
downregulated) and 52% decline (23 upregulated and 25 downregulated) in 
 
antiapoptotic genes in FD WT DMH, FD untreated, FA WT DMH and β-pol+/-
treated mice, respectively. Although apoptotic levels are inclined in FD WT DMH 
treated, CASP3, which is downstream in the apoptotic pathway, is significantly 
 
downregulated, whereas it is significantly upregulated in FD β-pol+/- DMH treated 
and unchanged in FD WT untreated or FA WT DMH treated mice (Table IX). 
 
Noting lack of DNA repair activity and elevation of apoptosis, specifically CASP3 
 
in FD β-pol+/- DMH treated mice; we wanted to determine the impact of PARP 
activity on colonic mucosa. 
 
Gene expression analysis of poly(ADP-ribose) polymerase (PARP) 
 
We  wanted  to  know  the  level  of  PARP  activity  as  it  plays  a  vital  role  in 
 
DNA  repair  and  programmed  cell  death.    The  most  widely  studied  PARP  is 
 
PARP1, which is activated mainly by SSBs or DSBs (170). Inhibition of PARP 
enzyme activity interferes with DNA base excision repair and leads to increased 
genetic instability and recombination but, on the other hand, can sensitize cells to 
apoptotic stimuli and by this mechanism may prevent tumor formation. While FD 
untreated mice show reduced or unchanged PARP expression, WT FD DMH 
mice display increased levels, specifically PARP1 and PARP3, which associates 
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with components of BER and NHEJ (171) or no change in gene expression and 
 
FA WT DMH as well, show elevated levels of PARP1 or no significant change, as 
 
did FD β-pol+/- DMH treated mice with the exception of PARP1 which is 
downregulated (Table X). When PARPs become elevated they signal for 
apoptosis or necrosis, which then becomes cleaved by CASP3 in order to 
prevent depletion of NAD. In this current study their is a reduction in PARP1 in 
 
FD β-pol+/- DMH treated mice and it appears as though the reduction in PARP1 
maybe related to its cleavage by CASP3. While PARP1 levels are elevated in 
both FD WT DMH and FA WT DMH treated mice CASP3 is either downregulated 
or unchanged in these animal models, respectively (Table IX). We suggest that 
 
the level of cellular toxicity imposed by FD β-pol+/- DMH treated mice causes a 
significant reduction in ATP levels hence the signaling for PARP1 cleavage by 
 
CASP3. 
 
Gene expression analysis of energy sensors 
 
Noting a reduction in ATP dependent chromatin remodeling machinery, 
DNA repair and PARP, as well as an increase in apoptotic activity, we wanted to 
know the impact of β-pol haploinsufficiency on energy sensing gene expression. 
 
Microarray analysis demonstrates a significant upregulation in energy sensing 
enzymes Cab39 (aka MO25), a scaffold protein that activates Stk11 (aka LKB1), 
and Stk11, a tumor suppressor kinase that phosphorylates and activates AMP-
activated protein kinase (AMPK) when cellular energy levels are low (172), in FD 
β-pol+/- treated mice (Table XI). In addition, Prkab1 (aka AMPK), which inhibits 
cell growth and proliferation through multiple pathways (172) is significantly 
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elevated in FD β-pol+/- treated mice. This information provides confirmation of 
energetic stress, consequently resulting in inhibition of cell survival and support 
of cell death. In view of these findings we wanted to look at the gene expression 
of downstream targets of AMPK that either produce ATP or consume it. 
 
Differential expression of genes in downstream events of AMPK 
 
Based on significant upregulation in expression of genes related to energy 
 
sensing, we wanted to know the impact of FD β-pol+/- DMH treatment on ATP-
producing versus ATP-consuming processes. Interestingly, we see a significant 
upregulation in expression of genes related to glucose uptake (GLUT4), 
glycolysis (Pfkfb3), and mitochondrial biogenesis (Ppargc1), all of which result in 
ATP-producing catabolic processes. In contrast, we see a downregulation in 
gene expression of enzymes involved in fatty acid synthesis (Acaca), sterol 
synthesis (Hmgcr), glycogen synthesis (Gys2) and protein synthesis (FRAP1), 
indicating a downregulation in ATP-consuming processes (Table XI). These 
findings suggest that amidst energy deprivation, cells react to try and conserve 
ATP. With the aforementioned, we decided to analyze gene expression levels 
related to the cell cycle pathway. 
 
Expression analysis of cell cycle related genes 
 
Knowing the differential expression apoptotic capacity in all animal 
models, we decided to study the effects of FD and DMH on cell cycle pathway 
gene expression to gather a further understanding of the series of events that 
take place in the cell leading to cell division and replication. We see relative little 
difference in gene expression related to cell cycle progression in FD DMH (67% 
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increase,  24  upregulated  and  12  downregulated),  FD  untreated  (65%  increase, 
 
25   upregulated   and   13   downregulated)   and   FA   DMH   (68%   increase,   32 
 
upregulated and 15 downregulated), respectively). Conversely, FD β-pol+/-
treated mice show a 65% downregulation in expression of genes related to cell 
cycle progression.(18 upregulated and 33 downregulated). Of interest, Cdk4 
which is important for cell cycle G1 phase progression and Cdk 6 for both 
progression and G1/S transition, cyclin E1, which forms a complex with cdk2 also 
 
for cell cycle G1/S transition, are all significantly downregulated in FD β-pol+/-
treated mice (Table XII). These cell cycle dependent genes are either 
significantly upregulated or not differentially expressed in all other experimental 
conditions. Additionally, we see a significant reduction in expression of genes 
related to cell cycle arrest in FD untreated (52%, 10 upregulated and 11 
downregulated), FD DMH treated mice (52%, 10 upregulated and 11 
 
downregulated) and FD β-pol+/- treated (55%, 13 upregulated and 16 
downregulated), whereas, FA DMH treated (55%, 17 upregulated and 14 
downregulated) shows significant increases in genes related to cell cycle arrest. 
 
Although genes related to cell cycle arrest are downregulated, it should be noted 
that P15 which forms a complex with Cdk4 or Cdk6, and prevents the activation 
of the Cdk kinases, p21 which binds to and inhibits the activity of cyclin-Cdk2 or - 
 
Cdk4  complexes,  p27,  which  binds  to  and  prevents  the  activation  of  cyclin  E- 
 
Cdk2 or cyclin D-Cdk4 complexes, are all downregulated in FD β-pol+/- treated 
mice (Table XII). All function as cell growth regulators that control cell cycle 
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G1/S  progression.   Having  discovered  all  of  these  findings,  we  wanted  to  know 
 
the expression of key genes related to the colorectal cancer pathway 
 
Gene expression analysis of genes related to colorectal cancer pathway 
 
Using  DAVID  bioinformatics  we  looked  at  the  colorectal  cancer  pathway 
 
gene expression. Interestingly, FD β-pol+/- DMH treated mice showed a 
decreased expression of genes downstream where these genes confer upon 
either proliferation or antiapoptotic activity. In particular, there is reduced 
expression of myc, which mediates the cellular response to growth factors and 
survivin, a member of the inhibitor of apoptosis, in β-pol haploinsufficiency 
exposed to DMH in a folate deficient environment. These genes are significantly 
upregulated or not differentially expressed in FDWT, FAWT DMH, and FDWT 
DMH (Table XIII). 
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Table VI. Summary of the effect of folate deficiency on folate pathway genes in wildtype, wildtypeDMH-
treated and β-pol+/- DMH-treated mice* 
 
Accession no. Gene name 
FDWT FAWT    FDWT     FDβ-pol+/-
 
 DMH DMH DMH  
    
NM_010840 5,10-methylenetetrahydrofolate reductase ns -1.2 -1.3 -1.3 
 
L26316 Dihydrofolate reductase ns 1.3 1.2 -1.8 
 
AI323028 Thymidylate synthase ns ns ns -1.9 
 
XM_138431 5-methyltetrahydrofolate-homocysteine methyltransferase ns ns ns -1.4 
 
NM_023595 Deoxyuridine triphosphatase ns ns 1.5 -1.5 
 
NM_145569 Methionine adenosyltransferase II, alpha ns ns ns 1.2 
 
AK038303 Methionine adenosyltransferase II, beta ns ns -1.4 1.5 
 
NM_010066 DNA methyltransferase (cytosine-5) 1 ns ns 1.4 -1.5 
 
NM_010067 DNA methyltransferase 2 -1.4 -1.4 -1.2 ns 
 
NM_007872 DNA methyltransferase 3A -1.2 ns -1.3 ns 
 
NM_010068 DNA methyltransferase 3B ns 1.5 1.3 -1.5 
 
NM_010321 Glycine N-methyltransferase ns ns ns 3.4 
 
BC015304 S-adenosylhomocysteine hydrolase ns ns ns -1.7 
 
* P<0.05; ns, no significant difference     
 
94 
 
 
 
Table VII. Summary of the effect of folate deficiency DNA pathway genes in wildtype, wildtypeDMH-
treated and β-pol+/- DMH-treated mice* 
 
Accession no. Gene name FDWT 
FAWT    FDWT     FDβ-pol+/- 
 
 DMH DMH DMH  
    
NM_009764 Breast Cancer 1 1.4 1.5 ns -1.8  
 
NM_009765 Breast Cancer 2 1.5 1.4 1.5 -1.4 
 
 
AF236887 Ataxia telangiectasia and Rad3 related 1.2 1.3 1.2 -1.3 
 
 
AK048970 Ataxia telangiectasia mutated homolog (human) ns ns ns -1.6 
 
 
NM_009012 RAD50 homolog ns ns ns -1.2 
 
 
NM_011236 RAD52 homolog (S. cerevisiae) 1.3 ns 1.2 -1.2 
 
 
NM_009015 RAD54 like 1.4 1.8 ns -2.0 
 
 
NM_011677 Uracil DNA glycosylase 1.2 1.8 1.6 -1.6 
 
 
NM_181569 N-methylpurine-DNA glycosylase ns ns ns -1.4 
 
 
NM_011561 Thymine DNA glycosylase ns ns ns -1.2 
 
 
NM_009687 Apurinic/apyrimidinic endonuclease 1 ns ns 1.4 -1.7 
 
 
AK047252 Polymerase (DNA directed), beta ns -1.8 -1.4 -1.5 
 
 
NM_021498 Polymerase (DNA directed), epsilon 3 (p17 subunit) ns ns ns -1.3 
 
 
NM_010715 Ligase I, DNA, ATP-dependent 1.2 1.4 1.5 -1.3 
 
 
NM_010716 Ligase III, DNA, ATP-dependent 1.3 1.3 ns -1.3 
 
 
AK048442 Ligase IV, ATP-dependent ns ns ns -1.4 
 
 
NM_008628 MutS homolog 2 1.3 ns 1.3 -1.5 
 
 
NM_133250 MutY homolog (E. coli) ns ns 1.3 -1.7 
 
 
NM_010829 MutS homolog 3 ns ns ns -1.4 
 
 
NM_146235 Excision    repair    cross-complementing    complementation 1.3 1.5 1.8 -2.3 
 
 
 
group 6 - Like 
     
 
NM_007949 Excision    repair    cross-complementing    complementation ns ns ns -1.3 
 
 
 
group 2 
     
 
NM_009531 Xeroderma pigmentosum, complementation group C ns ns ns -1.2 
 
 
NM_016926 Fanconi anemia, complementation group A 1.3 1.6 1.6 -1.4 
 
 
NM_175027 Fanconi anemia, complementation group B 1.3 1.5 ns -1.6 
 
 
NM_007985 Fanconi anemia, complementation group C ns ns ns -1.3 
 
 
NM_018736 Meiotic recombination 11 homolog A 1.2 ns ns -1.3 
 
 
NM_011045 Proliferating cell nuclear antigen ns 1.3 ns -1.3 
 
 
NM_009532 X-ray  repair  complementing  defective  repair  in  Chinese ns ns ns -1.2 
 
 
 
hamster cells 1 
     
 
NM_028875 X-ray  repair  complementing  defective  repair  in  Chinese ns ns ns -1.7 
 
 
 
hamster cells 3 
     
 
NM_009533 X-ray  repair  complementing  defective  repair  in  Chinese ns ns 1.2 -1.4 
 
 
 
hamster cells 5 
     
 
* P<0.05; ns, no significant difference      
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Table VIII. Summary of the effect of folate deficiency chromatin remodelling in wildtype, wildtypeDMH-
treated and β-pol+/- DMH-treated mice* 
 
Accession no. Gene name 
FDWT     FAWT    FDWT     FDβ-pol+/-
 
 
DMH DMH DMH 
 
     
 SWI/SNF    related,    matrix    associated,    actin    dependent     
 
NM_053123 regulator of chromatin, subfamily a, member 1 ns ns ns -1.5 
 
 
SWI/SNF    related,    matrix    associated,    actin    dependent 
    
 
NM_009211 regulator of chromatin, subfamily c, member 1 ns ns -1.3 -1.5 
 
 
Excision     repair     cross-complementing     rodent     repair 
    
 
NM_146235 deficiency complementation group 6 - like 1.3 1.5 1.8 -2.3 
 
NM_144958 Eukaryotic translation initiation factor 4A1 ns ns ns -1.4 
 
AK033272 AT rich interactive domain 1B (Swi1 like) ns ns ns -1.2 
 
NM_010436 H2A histone family, member X ns ns ns -1.6 
 
* P<0.05; ns, no significant difference     
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Table IX. Summary of the effect of folate deficiency apoptosis pathway in wildtype, wildtypeDMH-treated 
and β-pol+/- DMH-treated mice* 
 
Accession no. Gene name FDWT FAWT    FDWT     FDβ-pol
+/-
 
 
 DMH DMH DMH  
    
       
 
NM_008086 Growth arrest specific 1 -2.9 ns ns 8.8  
 
NM_011641 Transformation related protein 63 ns ns ns 27.4 
 
 
NM_009367 Transforming growth factor, beta 2 ns ns ns 11.4 
 
 
NM_008337 Interferon gamma ns -3.9 ns 4.1 
 
 
NM_008329 Interferon activated gene 203 1.4 2.2 2.3 4.0 
 
 
NM_009807 Caspase 1 ns ns ns 1.3 
 
 
NM_009812 Caspase 8 ns ns ns 1.4 
 
 
NM_007609 Caspase 4, apoptosis-related cysteine peptidase ns ns 1.5 2.1 
 
 
XM_139295 Caspase recruitment domain family, member 6 ns ns ns 1.4 
 
 
NM_175362 Caspase recruitment domain family, member 11 ns 1.4 1.2 1.7 
 
 
NM_011817 Growth arrest and DNA-damage-inducible 45 gamma ns ns ns 1.5 
 
 
AK010701 Death effector domain-containing DNA binding protein 2 -1.2 ns ns 1.6 
 
 
NM_025858 Scotin gene -1.2 ns 1.2 1.4 
 
 
NM_013693 Tumor necrosis factor ns ns ns 3.9 
 
 
NM_010177 Fas ligand (TNF superfamily, member 6) ns ns 3.2 2.1 
 
 
NM_009425 Mus  musculus  tumor  necrosis  factor  (ligand)  superfamily, -2.4 ns ns 2.0 
 
 
 
member 10 
     
 
NM_011614 Tumor necrosis factor (ligand) superfamily, member 12 ns ns ns 2.2 
 
 
NM_178589 Tumor necrosis factor receptor superfamily, member 21 ns ns ns 1.4 
 
 
NM_175649 Mus  musculus tumor  necrosis  factor receptor superfamily, ns ns ns 4.1 
 
 
 
member 26 
     
 
NM_183322 Nur77 downstream gene 1 -2.5 ns 3.9 3.0 
 
 
NM_009810 Caspase 3 ns ns -1.4 1.7 
 
 
* P<0.05; ns, no significant difference      
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Table X. Summary of the effect of folate deficiency on Poly (ADP-ribose) polymerase (PARP) in wildtype 
and DMH treated wildtype and Knockout mice* 
 
 
Accession no. Gene name 
FDWT FAWT    FDWT     FDβ-pol+/- 
 
 DMH DMH DMH  
    
X14206 Mouse mRNA for poly (ADP-ribose) polymerase ns ns ns -1.4 
 
NM_145619 Poly (ADP-ribose) polymerase family, member 3 ns ns 1.4 1.5 
 
BC025847 Poly (ADP-ribose) polymerase family, member 4 ns ns ns 1.6 
 
NM_027272 Poly (ADP-ribose)  polymerase  family,  member  8  (Parp8), -2.7 ns ns 2.9 
 
 
mRNA 
    
 
NM_181402 Mus   musculus   poly   (ADP-ribose)   polymerase   family, ns ns ns 1.5 
 
 
member 11 (Parp11), mRNA. 
    
 
NM_172893 Poly (ADP-ribose) polymerase family, member 12 ns -1.2 ns 1.6 
 
BC021340 Poly (ADP-ribose) polymerase family, member 14 ns ns 1.4 3.7 
 
NM_008904 Peroxisome     proliferative     activated     receptor,     gamma, ns -1.8 -1.7 1.19 
 
 
coactivator 1 alpha 
    
 
AK045690 Peroxisome     proliferative     activated     receptor,     gamma, ns ns ns 1.3 
 
 
coactivator 1 beta 
    
 
* P<0.05; ns, no significant difference     
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Table XI. Summary of the effect of folate deficiency on energy sensors, glucose uptake, glycolysis, fatty 
acid oxidation, mitochondrial biogenesis, fat acid synthesis, sterol synthesis, glycogen synthesis and protein 
synthesis in wildtype and DMH treated wildtype and Knockout mice* 
 
    FDWT FAWT FDWT FDβ-pol+/- 
 
Accession no. Gene name    DMH DMH DMH  
      
 
NM_133781 Calcium binding protein 39 
 
-1.2 -1.2 -1.3 2.1 
 
NM_011492 Serine/threonine kinase 11  1.2 ns ns 1.2 
 
NM_031869 Protein    kinase,    AMP-activated,    beta    1 ns ns ns 1.2 
 
 
non-catalytic subunit 
     
 
BC043920 FK506     binding     protein     12-rapamycin -1.3 ns ns -1.8 
 
 
associated protein 1 
     
 
NM_009204 Solute carrier family 2  (facilitated  glucose ns ns ns 1.7 
 
 
transporter), member 4 
     
 
NM_133232 6-phosphofructo-2-kinase/fructose-2,6- ns ns ns 2.0 
 
 
biphosphatase 3 
      
 
AK032149 Peroxisome proliferative activated ns ns -1.7 1.4 
 
 
receptor, gamma, coactivator 1 alpha 
    
 
BC023946 Acetyl-Coenzyme A carboxylase alpha ns ns ns -1.3 
 
NM_008255 3-hydroxy-3-methylglutaryl-Coenzyme   A ns ns -2.1 -1.6 
 
 
reductase 
      
 
NM_145572 Glycogen synthase 2 
 
ns ns ns -2.1 
 
* P<0.05; ns, no significant difference      
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Table XII. Summary of the effect of folate deficiency on cell cycle genes in wildtype and DMH treated 
wildtype and Knockout mice* 
 
  
FDWT      FAWT     FDWT      FDβ-pol+/- 
 
Accession no. Gene name  DMH DMH DMH  
    
 
NM_009870 Cyclin-dependent kinase 4 ns ns 1.4 -1.6 
 
NM_009873 Cyclin-dependent kinase 6 ns 2.2 ns -1.4 
 
NM_009874 Cyclin-dependent kinase 7 (homolog of Xenopus MO15 ns ns ns -1.3 
 
 
cdk-activating kinase) 
    
 
NM_007633 Cyclin E1 ns ns ns -1.5 
 
NM_172301 Cyclin B1 ns 1.4 1.3 -2.6 
 
NM_016756 Cyclin-dependent kinase 2 ns 1.4 ns -1.8 
 
NM_023284 Cell division cycle associated 1 ns 1.5 1.5 -1.7 
 
NM_175384 Cell division cycle associated 2 1.3 1.5 ns -2.1 
 
NM_007659 Cell division cycle 2 homolog A (S. pombe) ns ns 1.4 -2.5 
 
NM_013538 Cell division cycle associated 3 ns 1.2 ns -2.4 
 
NM_028023 Cell division cycle associated 4 ns 1.3 ns -1.2 
 
NM_026410 Cell division cycle associated 5 1.4 1.4 1.5 -1.9 
 
NM_025866 Cell division cycle associated 7 1.5 1.5 ns -1.7 
 
AK076422 Cell division cycle associated 8 ns 1.3 1.4 -2.3 
 
NM_010849 Myelocytomatosis oncogene 1.3 1.4 1.3 -1.2 
 
NM_007670 Cyclin-dependent   kinase   inhibitor   2B   (p15,   inhibits -1.2 ns ns 1.6 
 
 
CDK4) 
    
 
NM_007669 Cyclin-dependent kinase inhibitor 1A (P21) -1.4 -1.5 -1.4 1.3 
 
NM_009875 Cyclin-dependent kinase inhibitor 1B (P27) -2.5 -3.5 -1.5 1.2 
 
NM_007670 Cyclin-dependent   kinase   inhibitor   2B   (p15,   inhibits -1.3 ns ns 1.6 
 
 
CDK4) 
    
 
NM_009876 Cyclin-dependent kinase inhibitor 1C (P57) -1.7 -1.3 ns 1.4 
 
NM_009029 Retinoblastoma 1 1.6 -1.2 ns 1.2 
 
U59758 P53-variant (p53) ns ns ns -1.8 
 
NM_134092 Mdm2, transformed 3T3 cell double minute p53 binding 1.3 1.5 1.4 -1.5 
 
 
protein 
    
 
BI646741 MAD homolog 3 (Drosophila) ns -1.4 -1.4 1.6 
 
NM_008540 MAD homolog 4 (Drosophila) 1.2 -1.4 -1.5 ns 
 
NM_019827 Glycogen synthase kinase 3 beta -1.7 -1.4 -2.4 1.3 
 
AK048970 Ataxia telangiectasia mutated homolog (human) ns ns ns -1.6 
 
NM_007691 Checkpoint kinase 1 homolog (S. pombe) 1.5 1.8 1.7 -1.6 
 
NM_016681 Mus  musculus  CHK2  checkpoint  homolog  (S.  pombe) ns 1.3 ns -1.9 
 
 
(Chek2), mRNA. 
    
 
     
 
* P<0.05; ns, no significant difference     
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Table XII. Summary of the effect of folate deficiency on colon cancer genes in wildtype and DMH treated 
wildtype and Knockout mice* 
 
  FDWT FAWT FDWT FDβ-pol+/- 
 
Accession no. Gene name  DMH DMH DMH  
    
 
      
 
BI646741 MAD homolog 3 (Drosophila) ns -1.4 -1.4 1.6 
 
NM_008540 MAD homolog 4 (Drosophila) 1.2 -1.4 -1.5 ns 
 
AK036317 V-raf-leukemia viral oncogene 1 ns ns -2.2 1.5 
 
AK088784 Glycogen synthase kinase 3 beta -1.6 ns -2.4 1.3 
 
NM_015732 Axin2 1.4 ns ns -1.7 
 
AK039745 Adenomatosis polyposis coli -1.6 ns -1.3 1.7 
 
NM_010234 FBJ osteosarcoma oncogene -1.6 ns -1.3 1.5 
 
NM_010591 Jun oncogene ns ns ns 1.9 
 
NM_010849 Myelocytomatosis oncogene 1.3 ns 1.3 -1.4 
 
NM_016700 Mitogen activated protein kinase 8 ns ns ns -1.4 
 
NM_009689 Baculoviral IAP repeat-containing 5 ns ns ns -2.8 
 
* P<0.05; ns, no significant difference     
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Discussion 
 
We have previously shown the consequence of β-pol heterozygosity on 
the development and progression of ACF in DNA polymerase β heterozygous 
knockout mice of C57BL/6 background (122), characterized formerly in our lab 
(122). In these studies both wildtype and β-pol haploinsufficient mice did not 
display any ACF in their colon, indicating that β-pol haploinsufficiency and 
successive BER deficiency is not enough to induce ACF in mice on its own. This 
suggests that β-pol is a low penetrance gene requiring some other insult in the 
environment, such as an exposure to a chemical or a nutritional deficiency. 
Therefore, to induce ACF formation, we injected 30mg/kg i.p. 1,2-
dimethylhydrazine (DMH), a known colon and liver carcinogen, for 6 weeks. DMH 
produces alkylation damage (06-meG and N7-meG) as well as oxidative 
damage, damages we have shown (60) to be processed normally by the BER 
pathway. As expected, β-pol haploinsufficient mice, sacrificed 6 weeks after final 
DMH injection, showed a significant 67% higher level of ACF formation 
 
(29.7+1.4) as compared to their wildtype counterparts (15.4+1.8), indicating that 
 
β-pol+/- mice are more sensitive to both alkylation and oxidative damage. Noting 
these changes and having previously established that β-pol haploinsufficiency 
appears to mimic the effects of folate deficiency on the BER pathway, we then 
proceeded to look at the effect of folate deficiency (FD) on ACF formation in the 
 
β-pol+/-, for deficiency in this B vitamin has been implicated in colon 
carcinogenesis. Interestingly, FD in wildtype mice subject to DMH showed a 
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significant   increase   in   ACF   formation   (37.6+5.2)   relative   to   their   wildtype 
 
counterparts, however, when FD was imposed in the β-pol+/-, we saw a 50% 
decline in ACF formation (18.3+4.1) after DMH treatment. This indicated that β-
pol haploinsufficiency attenuated the carcinogen-induced ACF formation when 
folate was deficient. There was no significant difference in the number of 
aberrant crypts per focus 12 weeks after sacrifice. When mice were 
macroscopically observed 40 weeks post treatment there was an apparent 
regression in the number of ACF in DMH treated mice, however, there was a 
significant increase in the number of aberrant crypts per focus in FDWT mice 
relative to their WT counterparts (7.63+0.4 versus 6.33+0.4, respectively), 
indicating a progression of this disease. In addition, methylene blue staining of 
formalin-fixed colon tissue showed defined elevation of ACF above the 
surrounding mucosa in FD fed mice, while the FA mice displayed less developed 
 
ACF, providing further evidence of advanced ACF formation. Based on the 
progression of ACF, we decided to conduct proliferative and apoptotic assays to 
further visualize the growth changes of these aberrations. Interestingly, TUNEL 
assay results showed a significantly greater level of apoptotic activity, while BrdU 
assays showed significantly more proliferation (BrdU incorporation) in FD β-pol+/-
DMH treated colon mucosa compared to FAWT counterparts. Noting all of the 
aforementioned changes in colon morphology, we wanted to determine the 
impact of β-pol haploinsufficiency and FD on gene expression in colonic mucosal 
tissue. 
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Sequentially,    to    determine    possible    mechanisms    of    reduced    ACF 
 
formation and progression in β-pol+/-, we, in our current study, decided to conduct 
microarray analyses’ on FDWT, FAWT DMH treated, FDWT DMH treated and 
 
FD β-pol+/- DMH treated relative to FAWT colon mucosa. The genome-wide 
gene expression pattern in the colonic mucosa of these mice was investigated 
using the Affymetrix G4122A, Whole Mouse Genome and G4122F, Whole 
 
Mouse Genome. 
 
The present data support our previous findings of β-pol haploinsufficiency 
conferring a protective effect in the development of colon cancer. Firstly we 
 
determined the reduced expression of MTHFR, DHFR and TS in FD β- pol+/-
DMH treated colonic mucosa. In a study conducted by Tsourouflis et al., (173) in 
human colon cancer primary tumor specimen, they discovered a significant 
number of samples testing positive for TS, defining TS as an independent 
prognostic risk factor for colon cancer. Shimoda et al., (174), in their investigation 
on humans with pancreatic and biliary cancers likewise identified higher levels of 
TS in cancerous than noncancerous tissues. TS is necessary for 
 
DNA synthesis and has become therapeutic target for a number of cancers, 
particularly rapidly dividing cells that make vital use of their nucleotide synthesis 
machinery. Inhibition of TS results in an increase in dUTP pools, and incorporation 
of uracil into DNA. BER is responsible for the removal of uracil; however, when 
thymidylate is deficient and dUTP levels are elevated, uracil continually becomes 
misincorporated into the DNA leading to ‘catastrophic’ BER, with subsequent 
elevated levels of DSB and eventual cell death (175, 176, 177). 
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Peters  et  al.,  (178)  in  there  study  utilizing  high  doses  of  5-fluorouracil  (5-FU),  a 
 
TS inhibitor, on 5-FU-sensitive and -resistant human colon cancer cell lines 
demonstrated enhanced TS inhibition, which also prevented TS induction and 
increased the antitumor effect. In this study we determined a significant 
 
reduction in gene expression of MTHFR and DHFR in FD β- pol+/- DMH treated 
mice. Both of these enzymes catalyze reactions that require the use of energy in 
the form NADPH. 
 
Denoting the irregularity in folate metabolism, we studied the effects of β-
pol haploinsufficiency on the expression of DNA repair genes when DMH was 
injected in a folate deficient environment. We first looked at BER for BER has the 
primary role in processing the damage created by this environment. Genes 
related to BER were significantly downregulated in this animal model. Due to 
folate restriction there is a soaring elevation in uracil misincorporation. β-pol 
haploinsufficiency would lead to deficient BER activity giving rise to SSB which 
would eventually lead to DSB formation and the triggering of eventual cell death. 
In addition, we see an elevation in PARP gene expression, with the exception of 
 
PARP1 in β-pol+/-. PARPs are known to assist in the repair of single-strand DNA 
nicks, however, if significantly elevated, PARPs deplete ATP levels. Peterman et 
al., (179) using synthetic oligonucleotides, have shown a lack of short patch BER 
under conditions of ATP shortage. They also report maintenance of long patch 
BER through strand displacement by XRCC1 when ATP levels are reduced. 
Others, in their observations, show poly(ADP-ribose) being converted to ATP by 
pyrophsphorolytic cleavage using the pyrophosphate generated from dNTPs 
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during DNA repair synthesis (180). In our studied we see a reduced capacity of 
both short and long patch BER. Reduction in short patch repair could be 
explained by β-pol haploinsufficiency, as well as, a nucleotide and ATP shortage, 
whereas the altered ability for long patch repair may lie in the fact that, in addition 
to aforementioned, there is a downregulation in XRCC1, as well, there is a 
reduction in PARP1, a gene necessary for recruitment of BER enzymes to sites 
of DNA damage. 
 
Homologous Recombination (HR) and non-homologous end-joining 
(NHEJ) are instrumental in the repair of DSB that can incur as a result of 
persistent BER intermediates. Yang et al., (181) studied the effect of thymidylate 
deprivation, through raltitrexed (RTX), in H-29 human colon cancer cells and 
HeLa human cervical cancer cells. Their results show an induction of HR which 
influences a cellular resistance to RTX. Using RTX treated cell line 9-2, which 
was derived by stably transfecting GM00637 cells with pTNeo99-7, Waldman et 
al., (182) demonstrated adequate NHEJ. In our study we see a reduction in a 
number of HR/NHEJ related genes with β-pol haploinsufficiency, implying that 
another causative effect is occurring other than thymidylate deprivation for 
reduced HR/NHEJ repair capacity. We propose that in addition to lack of 
thymidine, nucleotide and ATP shortage, as well as reduced PARP1 activity may 
result in the deficiency of DSB repair. It should be noted that β-pol 
haploinsufficiency in our damage inducible environment shows significant 
downregulation in genes related to HR/NHEJ, ATM, ATR and DNA-pk 
expression. 
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Recent evidence has suggested that a histone code, which involves 
phosphorylation, ubiquitylation, sumolation, acetylation and methylation is 
involved in DNA damage detection and DNA repair. It is predicted that this code 
allows for modification on a specific histone tail that can be read by other 
chromatin associated proteins (183). Chromatin modification is accomplished by 
a chromatin-remodeling complex, which are a family of ATP-dependent 
molecular machines that participate in transcriptional regulation, DNA repair, 
homologous recombination and chromatin assembly (164). The chromatin-
remodeling complex can destabilize histone-DNA interactions in reconstituted 
nucleosomes in an ATP-dependent manner, though the exact nature of this 
structural change is unknown. This code becomes important for DNA repair, for 
histone modification is necessary for all repair machineries to gain access to 
 
DNA in order to proceed (183). In this study FD β- pol+/- DMH treated mice show 
significant downregulation in genes relative to the ATPase dependent chromatin 
remodeling complex. 
 
In addition to a potential lack of exposure of DNA in chromatin, our study 
shows a distinct downregulation in H2A related gene expression. A specific 
subtype of H2A, called H2afx (aka H2AX), which plays a very important role in 
the cellular response to DNA damage and participates in DNA double-strand 
break repair is significantly downregulated in β-pol haploinsufficiency upon 
exposure to DMH in a folate deficient environment. This enzyme is normally 
phosphorylated by ATM/ATR (involved in HR) or by DNA-pk (involved in NHEJ) 
(183, 184, 184). These 3 aforementioned genes, as previously stated, are 
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downregulated in FD β- pol+/- DMH treated mice. Upon phosphorylation of 
H2AX, then called γ-H2AX, it co-localizes to nuclear foci at sites of DNA damage 
(186). γ-H2Ax is believed to then recruit checkpoint proteins such as BRCA1, 
MRE11/RAD50/NBS1 complex, MDC1 and 53BP1 to the site of DNA damage 
(187). Interestingly, with the exception of MDC1, all the aforementioned genes 
 
are significantly downregulated in FD β- pol+/- DMH treated mice. Hong et 
al.(188), in there study utilizing WTHBF-6 cells derived from primary human 
bronchial fibroblasts, demonstrated a co-localization of Mre11 to gamma-H2A.X 
and ATM when cells were exposed to Hexavalent chromium, an agent that 
induces DNA double strand breaks. Here we see lack of induction of ATM/ATR 
or DNA-pk inferring inhibition of phosphorylation of H2AX disallowing DNA repair 
to occur via HR and NHEJ. 
 
Our   current   study   shows   a   lack   of   expression   of   PARP1.     PARP1 
 
catalyzes the conversion of NAD+ into nicotinamide and poly(ADP-ribose) and is 
shown to be required for genome repair, DNA replication and the regulation of 
transcription (189). Liu et al. (190), in their study using HeLa cells treated with 
MNNG and ABT-888, a potent PARP inhibitor, facilitated the induction of 
apoptosis without a reduction in the level of ATP. Similarly, Ghosh et al. (191), 
showed PARP1 inhibition through Benzamide in HeLa cells resulted in an 
induction of apoptosis under mild oxidative stress. They also demonstrate that 
reduced PARP1 results in an increase in nuclear fragmentation and increased 
 
caspase 3 activity along with an increase in cellular NAD+ levels. In addition, a 
decrease in general poly(ADP-ribosyl)ation is seen. It should be noted that the 
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extensive DNA damage caused overactivation of PARP1 followed by severe ATP 
depletion which is hence causative of necrotic cell death (192). Interestingly, FD 
β-pol+/- DMH treated mice show significant downregulation in Apoptosis-inducing 
factor (AIR)-like mitochondrion-associated inducer of death and Endonuclease G, 
genes involved in necrosis. Boulares et al. (193), using human osteosarcoma 
cells show that PARP1 cleavage during apoptosis is required for both the 
prevention of excessive depletion of NAD and ATP and to release of DNase1L3. 
 
DNase1L3  is  inhibited  by  poly(ADP-ribosyl)ation.    DNase1L3  is  upregulated  in 
 
FD β-pol+/- DMH treated mice indicating a lack of its ribosylation and instead acts 
to mediate the breakdown of DNA during apoptosis. In a study on primary 
myeloid leukemic cells and myeloid leukemic cell lines which have double strand 
DNA repair defects, Gaymes et al. (194) used PARP inhibitors, KU-0058948 and 
 
PJ34, which induced cell cycle arrest and apoptosis. This study depicts a 
downregulation in PARP1. It is currently unknown if this effect is either via 
cellular signaling to reduce its expression or as a result of CASP3 activity. 
Regardless,  this  reduced  expression  appears  to  enlist  apoptosis.   In  this  study, 
 
FD β-pol+/- DMH treated mice show a significant upregulation in expression of 
apoptotic genes. The lack of expression of necrotic genes would indicate that 
 
the activity occurring in the mucosal cells of FD β-pol+/- DMH treated mice is of 
low cellular energetic stress, however, not to the degree where death is induced 
via necrosis. 
 
FD β-pol+/- DMH treated mice show an increase in expression of cellular 
energy stress sensors, including CAB39 and STK11 confirming energetic stress 
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in this environment. In response to energy stress, cells activate AMPK 
downstream of the tumor suppressor, STK11. We also see an increase in 
expression of APRT which catalyzes the formation of AMP and inorganic 
pyrophosphate from adenine and 5-phosphoribosyl-1-pyrophosphate (PRPP) 
indicating an elevation in the level of AMP/ATP ratio. Interestingly, Prkab1 
 
(AMPK), which is elevated in FD β-pol+/- DMH treated mice, is activated when 
intracellular levels of ATP decline and intracellular levels of AMP increase (195), 
the former allosterically activating Prkab1 (196). These findings seem to mimic 
the effects of AMP-mimetic AICAR, which is a pharmacological target of human 
cancers that suppress cancer cell growth (197). In addition to elevated energy 
sensing genes there is also an increase in expression of CaMKK (CaMKK2), 
another physiological activator of AMPK (198). STK11 and CaMKK are two 
kinases that phosphorylate AMPK for its activation (199). Yee et al. (200), in 
there study on cervical cancer cell lines reveal that, A23187, an alternative 
pharmacological AMPK activator inhibits cancer cell growth through CaMKK. 
 
Increased intracellular Ca2+ causes an increase in CaMKK (199). Chern et al. 
(201), utilizing human hepatoma Hep G2 cells, showed an overproduction of 
hydrogen peroxide as a result of the oxidative stress imposed by folate deficiency 
which ultimately led to cell death through apoptosis. Satu et al. (203), in their 
study on rat hepatocytes demonstrate H2O2 impairment of mitochondrial 
 
function via oxidative stress, that reduces intracellular ATP production, and in 
turn opens ATP-sensitive, non-specific cation channels, leading to Ca2+ influx 
which can trigger apoptosis.    CaMKK is upregulated in FD β-pol+/-  DMH 
treated 
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mice and is downregulated in FD WT untreated animals. These findings would 
indicate that the oxidative stress imposed by FD in β-pol haploinsufficiency would 
result in increased intracellular calcium levels leading to CaMKK activation of 
 
AMPK, as well as, the induction of apoptosis. 
 
AMPK  is  known  to  maintain  a  balance  between  ATP  production  and  its 
 
consumption in all eukaryotic cells. In this current study FD β-pol+/- DMH treated 
mice show compromised energy status thus activating catabolic pathways while 
diminishing macromolecule biosynthesis, cell growth and proliferation through 
AMPK. We see an increase in GLUT4 expression which induces glucose uptake, 
Pfkfb3, upregulating glycolysis and Ppargc1, implicated in increased 
mitochondrial biogenesis. Additionally we see a decrease in Acaca expression, 
indicative of a reduction in fatty acid synthesis, Hmgcr, involved in sterol 
 
synthesis, GYS2, causing a decrease in glycogen synthesis (FD β-pol+/- DMH 
treated mice show an upregulation of GSK3b which inhibits GYS2) and an 
increase in EF2K which inhibits both protein synthesis and mTOR activity (203). 
All of these findings are not significantly altered in all other animal models with 
the exception of an increase in Acaca and downregulated expression of mTOR in 
 
FD WT mice. This would indicate that β-pol haploinsufficiency subject to 
prolonged FD subsequent to DMH treatment activates AMPK, switching on ATP 
on ATP-generating pathways, like glycolysis, but also switches off ATP-
consuming biosynthetic pathways. 
 
In this study we demonstrate an inhibition of gene expression related to 
cell growth and an upregulation in expression of cell cycle arrest genes in FD β- 
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pol+/- DMH treated mice. We show that β-pol haploinsufficiency 1) induces G1 
and G2/M arrest; 2) downregulates cdk4/6, cdk2, ccne1, cdc2a and ccnb1 
expression; and 3) upregulates gene expression of cdkn1a (p21), cdkn1b (p27), 
cdkn2b (p15) and cdkn1c (p57). Autonomy of growth signals and avoidance of 
cell death has been described by Hanahan et al. (204) as two of the six 
necessary changes in cell physiology that dictate malignant growth. Therefore, 
our animal model has the ability to induce apoptosis and inhibit cell cycle 
progression in colon cancer, and as such these mechanisms may potentially be 
utilized in the chemoprevention of colon cancer. 
 
Lastly, we looked at expression of  genes relative to the colorectal cancer 
 
pathway. Interestingly, FD β-pol+/- DMH treated mice show a reduction of 
expression of genes downstream of this pathway. Namely, there is a reduction in 
survivin which is an antiapoptotic gene, as well as, Myc which encourages 
proliferation. Expression of these are either unchanged or show opposite 
 
correlation to FD β-pol+/-  DMH treated in all other animals tested. 
 
In January of 1998, the United States imposed mandatory fortification of 
enriched cereal-grain products with folic acid to help prevent pregnancies 
affected by a neural tube defect (NTD) and potentially other malformations in 
their babies like cleft palate and lip and cardiac defects. Previous research 
suggested that folate deficiency appeared to play an important pathogenic role in 
the development of many disease states beyond NTDs including cardiovascular 
disease, Alzheimer’s disease and cancer (205). Due to the fact that the 
prevention effort targeted preconceptional women of child-bearing age, the 
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mandate exposed the entire population to this enrichment. This seemed feasible 
for folate is by and large regarded as safe and advantageous for disease 
prevention. The premise of this endeavor is working for the data from the 1999 to 
2000 National Health and Nutrition Examination Survey (NHANES) revealed a 
considerable increase in median serum folate concentrations in nonpregnant 
women of childbearing age compared to 1988 to 1994. Our current findings 
suggest that this massive effort to eradicate folate deficiency maybe detrimental 
under certain conditions, particularly certain cancers. Here we show that a 
deficiency in this B-vitamin may confer a protective effect in colon 
carcinogenesis. These findings seem sensible for if one considers the needs of 
rapidly dividing preneoplastic lesions like the ACF, folate would supply the 
necessary environment, principally to repair machinery, which ultimately may 
inflict more damage due to erroneous repair. Our findings imply that folate 
deficiency is needed in conjunction with a BER deficiency in order to reduce 
repair of damage created by this vitamin deficit, not only by BER but as well, 
repair by other pathways. 
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Summary and Future Directions 
 
Folate has emerged as an important nutritional element in the 
pathogenesis of several malignancies, including cancers of the colorectum, lung, 
pancreas, esophagus, stomach, cervix, and breast, as well as neuroblastoma 
and leukemia. Studies have collectively implied an inverse association between 
both dietary and serum folate and the risk of malignancy (1, 2); the most 
evidence relating to colorectal cancer (CRC) (3, 4). This information would 
appear, in light of these current studies, to be counterintuitive. Folate is 
especially important during periods of rapid cell division and growth such as seen 
in neoplastic cells. In addition, folate deficiency reduces intracellular nucleotide 
precursor pools; increasing uracil misincorporation and DNA strand breaks (5, 6) 
measures that would seem beneficial for the suppression of cancer cells. 
 
Here we show that folate deficiency not only suppresses onset and 
progression of ACF but in addition appears to reduce the level of cellular energy 
such that cells do not have the power to maintain viability. This study 
demonstrates an inhibition of nucleotide synthesis through an interruption in the 
folate pathway, chromatin condensation, an arrest in cell cycle progression and 
cellular signaling to energy sensors when β-pol is haploinsufficient in a folate 
deficient environment. In addition, we show reduced DNA repair and increased 
apoptotic activity. We propose that the oxidative and alkylation damage imposed 
by folate and DMH treatment resulted in the recruitment of PARPs to the sites of 
 
DNA damage. With a lack of β-pol, damage created would continually signal for 
repair, bringing in an abundance of PARP. This in turn would result in a 
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reduction in the mitochondrial membrane potential and ATP depletion leading to 
energy failure and cell death. PARP-1 activation leads to ATP depletion and 
necrosis (205, 206). Here we propose that as a result of PARP1 abundance, the 
apoptotic pathway is signaled leading to activation of caspases which cleave 
PARP1 and thereby preserve ATP. As seen in this current study, PARP1 is 
downregulated, switching the mode of death from necrosis to apoptosis, as seen 
by lack of response by necrotic enzymes but a significant increase in apoptotic 
activity. Here we suggest that after immediate exposure to DMH, PARP1 is 
recruited to sites of DMH damage, however, a deficient BER leads to elevated 
PARP activity. This elevation creates cellular energetic stress, signaling 
apoptosis or necrotic cell death. Having theorized this, PARP levels immediately 
after final injection such be ascertained. Six weeks after the final DMH injection, 
however, PARP1 activity is reduced leading to apoptosis signifying the level of 
ATP depletion governs the mode of cell death. Similar findings were reported by 
 
Ha et al. (206) in their study using fibroblasts of PARP−/− animals after exposure 
to either MNNG or H2O2. Other modes of DNA repair are reduced possibly 
 
secondary to apoptotic cell signaling, lack of induction of PARP activity, reduced 
cellular energy levels to mediate repair and by the lack of sufficient purine and 
pyrimidine synthesis. Lastly, current chemotherapeutic regimens for all causes of 
colon cancer utilize the same therapeutic agents; oxaliplatin, an alkylating agent 
proposed to prevent DNA synthesis, 5-fluorouracil (5-FU), an inhibitor of 
thymidylate synthase, and leucovorin, which enhances the binding of 5-FU in the 
cell while providing a source of folic acid for normal cells. While the premise is 
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understandable to some degree, questions arise regarding 5FU in the cancer cell 
and the continuance of ‘catastrophic’ repair by sufficientBER machinery. Thus, 
our findings appear to have both therapeutic and protective implications against 
the development and progression of colon cancer by means of an alteration in 
micronutrients when β-pol variants/polymorphisms exist. 
 
Future Directions 
 
Having elucidated the potential mechanism behind colon cancer 
prevention, future studies would include a repeat of experimental procedures on 
mice sacrificed immediately after final DMH injection and after approximately 40 
weeks to denote significant changes that occurs at these times as compared to 
our current 6 week after final injection sacrifice. This would assist in determining 
cellular performance immediately after exposure to and after an extensive time 
period without DMH. Studies should also be conducted on both 
ACF and normal adjacent tissue extracted through laser micro-dissection to 
delineate if there is a distinction in these tissues with respect to the key findings 
of our current study. We propose that ACF have greater metabolic needs than 
 
normal tissue. FD β-pol+/- DMH treated mice would have such a high level of 
metabolic stress that energy levels become so depleted that apoptosis would 
ensue. In contrast, with efficient BER, PARP levels would remain stable, allowing 
for repair and thus no lack ATP levels accelerating mutational frequency. As well, 
PARP1 cleavage should be assessed, for high levels of this enzyme without BER 
would cause severe cellular energy depletion and signal for its cleavage via 
caspases. In addition, it seems relevant to test the effects of 
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caloric restriction (CR) in β-pol haploinsufficiency when subject to DMH, for 
research has shown CR to increases life expectancy but as well, it would help 
delineate if what is found in our current study is a result of folate in a β-pol 
deficient environment or is it that folate depletes cellular energetic stores through 
the various aforementioned mechanisms and that CR could in fact mimic these 
findings. As well, it would be interesting to test the effects of β-pol 
haploinsufficiency in both the APC min mouse and MMR deficient mouse models 
fed a folate deficient diet, to test our current findings of protection when BER is 
deficient. 
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The data presented in this research is central to establishing the role that 
the base excision repair pathway (BER) plays in the development and 
progression of colon cancer when dietary folate is deficient. Both cellular folate 
restriction and BER deficiencies have been shown to result in the accumulation 
of endogenous damage and lesions that could eventually develop into 
carcinogenesis. In this study, a dietary folate deficiency (FD) resulted in a 
significant increase in aberrant crypt foci (ACF) formation and triggered liver 
tumorogenesis in wildtype (WT) animals, as did a BER deficiency in DNA 
polymerase β haploinsufficient (β-pol+/-) mice exposed to 1, 2-dimethylhydrazine 
(DMH), a known colon and liver carcinogen. We combined both folate restriction 
and a BER deficiency to determine the fate of colon tissue after exposure to 
DMH. Of interest, we show that this model supports a protection against colon 
carcinogenesis. FD attenuated onset and progression of ACF and prevented liver 
tumorigenesis in β-pol haploinsufficient mice. Analysis of the data suggests 
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that the mechanism by which this phenomenon occurs appears to be through an 
elevation in DNA damage that signals recruitment of PARP enzymes to the site 
of damage, however, with a deficiency in BER, PARP function in DNA repair is 
futile leading to a depletion of cellular energetic levels. This energetic stress is 
sensed by cell death machinery and as such apoptosis is invoked. 
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